Osteoporosis, a chronic progressive disease of multifactorial etiology (see Etiology), is the most common metabolic bone disease in the United States. It has been most frequently recognized in elderly white women, although it does occur in both sexes, all races, and all age groups.

This disease is considered a "silent thief" that generally does not become clinically apparent until a fracture occurs (see Clinical Presentation). Screening at-risk populations is, therefore, essential (see Workup).

Osteoporosis can affect almost the entire skeleton. It is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility.[1] The disease often does not become clinically apparent until a fracture occurs.

Osteoporosis represents an increasingly serious problem in the United States and around the world. Many individuals, male and female, experience pain, disability, and diminished quality of life as a result of having this condition. The economic burden the disease imposes is already considerable and will only grow as the population ages.[2]

Despite the adverse effects of osteoporosis, it is a condition that is often overlooked and undertreated, in large part because it is so often clinically silent before manifesting in the form of fracture. For example, a Gallup survey performed by the National Osteoporosis Foundation revealed that 75% of all women aged 45-75 years have never discussed osteoporosis with their physicians. Failure to identify at-risk patients, to educate them, and to implement preventive measures may lead to tragic consequences.

Medical care includes calcium, vitamin D, and antiosteoporotic medication such as bisphosphonates and parathyroid hormone. Antiresorptive agents currently available for osteoporosis treatment include bisphosphonates, the selective estrogen-receptor modulator (SERM) raloxifene, calcitonin, and denosumab. One anabolic agent, teriparatide (see

Medication), is available as well. Surgical care includes vertebroplasty and kyphoplasty. (See Treatment and Management.)

Osteoporosis is a preventable disease that can result in devastating physical, psychosocial, and economic consequences. Prevention and recognition of the secondary causes of osteoporosis are first-line measures to lessen the impact of the disease (see the images below). Osteoporosis of the spine. Observe the considerable reduction in overall vertebral bone density and note the lateral wedge fracture of L2. Osteoporosis of the spine. Note the lateral wedge fracture in L3 and the central burst fracture in L5. The patient had suffered a recent fall.

For more information, see Pediatric Osteoporosis, as well as Osteoporosis in Solid Organ Transplantation, Utility of Bone Markers in Osteoporosis, and Nonoperative Treatment of Osteoporotic Compression Fractures. Anatomy

Cortical and trabecular (cancellous) bone differ in architecture but are similar in molecular composition. Bone consists of cells and an extracellular matrix with mineralized and nonmineralized components. The composition and architecture of the extracellular matrix is what imparts mechanical properties to bone. Bone strength is determined by collagenous proteins (tensile strength) and mineralized osteoid (compressive strength).[3] The greater the concentration of calcium, the greater the compressive strength. Pathophysiology

Osteoporosis is a condition in which bone mass is low and microarchitectural deterioration of bone tissue occurs, leading to bone fragility and an increased risk of fracture. It results from hereditary and environmental factors that affect both bone mass and bone quality.

Traditionally, osteoporosis was described as type I (postmenopausal) or type II (senile). Postmenopausal osteoporosis (PMO) is primarily due to estrogen deficiency; senile osteoporosis is primarily due to an aging skeleton and calcium deficiency. However, it is increasingly recognized that multiple pathogenetic mechanisms interact in the development of the

osteoporotic state, regardless of age. Understanding the pathogenesis of osteoporosis starts with knowing how bone formation and remodeling occur. Normal bone formation and remodeling

Homeostasis of bone, a living tissue, is maintained by osteoclasts, which are responsible for bone resorption, and osteoblasts, which are responsible for bone formation. Osteoblasts are derived from mesenchymal stem cells, whereas osteoclasts are derived from hematopoietic precursors. The 2 types of cells are dependent on each other for production. In fact, the development of osteoclasts from hematopoietic precursors cannot be accomplished unless mesenchymal cells are present.

Mesenchymal cells with the potential to become osteoblasts also have the potential to become fibroblasts, chondrocytes, adipocytes, or muscle cells. This potential for differentiation allows the osteoblast to secrete the same cytokines and colony-stimulating factors produced by fibroblasts.

Hematopoietic granulocyte-macrophage colony-forming units (CFUs) produce osteoclasts and give rise to monocytes and macrophages. As such, the osteoclasts produce the same cytokines that monocytes produce. Interleukin (IL)-6 is produced, in part, by osteoblasts that stimulate osteoclastic activity. This phenomenon is one proposed mechanism for certain diseases that exhibit increased bone resorption. Two examples of diseases that result in osteoporosis by this mechanism are multiple myeloma and rheumatoid arthritis.

Bone is continually remodeled throughout life because bones sustain recurring microtrauma. Bone remodeling occurs at discrete sites within the skeleton and proceeds in an orderly fashion. Bone resorption is always followed by bone formation, a phenomenon referred to as coupling. In osteoporosis, this coupling mechanism is thought to be unable to keep up with the constant microtrauma to trabecular bone. In adults, approximately 25% of trabecular bone is resorbed and replaced every year, compared with only 3% of cortical bone.

Osteocytes, which are terminally differentiated osteoblasts embedded in mineralized bone, direct the timing and location of remodeling. Osteoblasts not only secrete and mineralize osteoid but also appear to control the bone resorption carried out by osteoclasts. Osteoclasts require weeks to

Under physiologic conditions. RANKL binds to the RANK receptor expressed by osteoclasts and osteoclast precursors to promote osteoclast differentiation. in periods of rapid remodeling (eg. after menopause). the resorption sites are temporarily unfilled. it is now understood that the receptor activator of nuclear factor-kappa B ligand (RANKL)/receptor activator of nuclear factor-kappa B (RANK)/osteoprotegerin (OPG) system is the final common pathway for bone resorption. . Accelerated bone loss can occur in perimenopausal women and elderly men and women and can occur secondary to various disease states and medications. bone is at an increased risk for fracture because the newly produced bone is less densely mineralized. A change in either—that is. In fact. and the isomerization and maturation of collagen is impaired. Therefore. Therefore. Bone mass peaks by the third decade of life and slowly decreases afterward. For example. Nevertheless.[5] Molecular biologists have begun to elucidate the mechanisms of bone remodeling. whereas osteoblasts need months to produce new bone. nutrition and physical activity are important during growth and development. any process that increases the rate of bone remodeling results in net bone loss over time.[6] Alterations in bone formation and resorption The hallmark of osteoporosis is a reduction in skeletal mass caused by an imbalance between bone resorption and bone formation. bone formation and resorption are in a fair balance. Osteoporosis can be caused both by a failure to build bone and reach peak bone mass as a young adult and by bone loss later in life. The failure to attain optimal bone strength by this point is one factor that contributes to osteoporosis. hereditary factors play the principal role in determining an individual's peak bone strength.[4] Furthermore.resorb bone. Osteoblasts and activated T cells in the bone marrow produce the RANKL cytokine. genetics account for up to 80% of the variance in peak bone mass between individuals. Osteoprotegerin is a soluble decoy receptor that inhibits RANKRANKL by binding and sequestering RANKL. increased bone resorption or decreased bone formation—may result in osteoporosis.

The production of IL-1 is increased in bone marrow mononuclear cells from ovariectomized rats. Estrogen deficiency can lead to excessive bone resorption accompanied by inadequate bone formation. and osteoclasts all express estrogen receptors. in which either the mice's ovaries were removed or sham operations were performed. found that IL-6 and granulocyte-macrophage CFU levels were much higher in the ovariectomized mice. estrogen affects bones indirectly through cytokines and local growth factors. IL-6. Administering IL-1 receptor antagonist to these animals prevents the late stages of bone loss induced by the loss of ovarian function. In contrast to postmenopausal bone loss. thus contributing to osteoporosis. and prolonged survival via IL-1. IL-1 has also been shown to be involved in the production of osteoclasts. and tumor necrosis factor (TNF)-alpha. The lack of gonadal hormones is thought to up-regulate osteoclast progenitor cells. see below). A murine study. In the absence of estrogen. The increase in the IL-1 in the bone marrow does not appear to be a triggered event. which is associated with excessive osteoclast activity. T cells promote osteoclast recruitment. but is a result of removal of the inhibitory effect of sex steroids on IL-6 and other genes directly regulated by sex steroids. osteocytes. and IL-6 contributes to the recruitment of osteoclasts from the monocyte cell line.Loss of gonadal function and aging are the 2 most important factors contributing to the development of osteoporosis. Estrogen deficiency not only accelerates bone loss in postmenopausal women but also plays a role in bone loss in men. but it does not prevent the early stages of bone loss.[7] This finding provided evidence that estrogen inhibits IL-6 secretion. In addition. estrogen deficiency sensitizes bone to the effects of parathyroid hormone (PTH. differentiation. Studies have shown that bone loss in women accelerates rapidly in the first years after menopause. T cells also inhibit osteoblast differentiation and activity and cause premature apoptosis of osteoblasts through cytokines such as IL-7. Finally. the bone loss that accompanies aging is associated with a progressive decline in the supply of . Osteoblasts. The estrogen-replete state may enhance osteoclast apoptosis via increased production of transforming growth factor (TGF)-beta.

[8] Polymorphisms of IL-1. Other factors implicated in the pathogenesis of osteoporosis include polymorphisms in the vitamin D receptor. and plays a minor role in bone resorption.25[OH]2 D. as well as their receptors. and . Women lose 30-40% of their cortical bone and 50% of their trabecular bone over their lifetime. Corticosteroids inhibit osteoblast function and enhance osteoblast apoptosis. vitamin D. osteoporosis.[4] Osteoporotic fractures represent the clinical significance of these derangements in bone. collagen abnormalities. and leukotrienes. such as falls from a sitting or standing position. Calcium. It increases calcium resorption from bone.25[OH]2 D)—an active hormonal form of vitamin D that optimizes calcium and phosphorus absorption. as opposed to men. decreases renal calcium excretion. glucocorticoids) can cause osteoporosis. prostaglandin E2. in severe situations. Vitamin D deficiency can result in secondary hyperparathyroidism via decreased intestinal calcium absorption. Insufficient dietary calcium or impaired intestinal absorption of calcium due to aging or disease can lead to secondary hyperparathyroidism.[3] Endocrinologic conditions or medications that lead to bone loss (eg. Interestingly. After the third decade of life. and increases renal production of 1.25-dihydroxyvitamin D (1. inhibits PTH synthesis.25[OH]2 D on bone are mediated via binding to osteoblasts and stimulating the RANKL/RANK pathway. They can result both from low-energy trauma. nitrous oxide.osteoblasts in proportion to the demand. alterations in insulin-like growth factor-1. IL-6 and TNF-alpha. who lose 15-20% of their cortical bone and 25-30% of trabecular bone. This demand is ultimately determined by the frequency with which new multicellular units are created and new cycles of remodeling are initiated. have been found to influence bone mass. the effects of PTH and 1. bone morphogenic protein. Osteoclasts do not have receptors for PTH or 1. and PTH help maintain bone homeostasis. and leptin-related adrenergic signaling. bone resorption exceeds bone formation and leads to osteopenia and. PTH is secreted in response to low serum calcium levels.

from high-energy trauma, such as a pedestrian struck in a motor vehicle accident. Fragility fractures, which occur secondary to low-energy trauma, are characteristic of osteoporosis.

Fractures occur when bones fall under excess stress. Nearly all hip fractures are related to falls.[9] The frequency and direction of falls can influence the likelihood and severity of fractures. The risk of falling may be amplified by neuromuscular impairment due to vitamin D deficiency with secondary hyperparathyroidism or corticosteroids.

Vertebral bodies are composed primarily of cancellous bone with interconnected horizontal and vertical trabeculae (see Anatomy). Osteoporosis not only reduces bone mass in vertebrae but also decreases interconnectivity in their internal scaffolding.[3] Therefore, minor loads can lead to vertebral compression fractures.

An understanding of the biomechanics of bone provides greater appreciation as to why bone may be susceptible to an increased risk of fracture. When vertical loads are placed on bone, such as tibial and femoral metaphyses and vertebral bodies, a substantial amount of bony strength is derived from the horizontal trabecular cross-bracing system. This system of horizontal crossbracing trabeculae assists in supporting the vertical elements, thus limiting lateral bowing and fractures that may occur with vertical loading.

Disruption of such trabecular connections is known to occur preferentially in patients with osteoporosis, particularly in postmenopausal women, making females more at risk than males for vertebral compression fractures.

Rosen and Tenenhouse studied the unsupported trabeculae and their susceptibility to fracture within each vertebral body and found an extraordinarily high prevalence of trabecular fracture callus sites within vertebral bodies examined at autopsy, typically 200-450 healing or healed fractures per vertebral body.[10] These horizontal trabecular fractures are asymptomatic, and their accumulation reflects the impact of lost trabecular bone and greatly weakens the cancellous structure of the vertebral body.

The reason for preferential osteoclastic severance of horizontal trabeculae is unknown. Some authors have attributed this phenomenon to overaggressive osteoclastic resorption.

Osteoporosis may be confused with osteomalacia. The normal human skeleton is composed of a mineral component, calcium hydroxyapatite (60%), and organic material, mainly collagen (40%). In osteoporosis, the bones are porous and brittle, while in osteomalacia the bones are soft. This difference in bone consistency is related to the mineral-to-organic material ratio. In osteoporosis, the mineral-to-collagen ratio is within the reference range, whereas in osteomalacia, the proportion of mineral composition is reduced relative to organic mineral content. WHO definition of osteoporosis

Bone mineral density (BMD) in a patient is related to peak bone mass and, subsequently, bone loss. The World Health Organization (WHO) has established the following definitions of osteoporosis based on BMD measurements in white women: Normal - BMD within 1 standard deviation (SD) of the mean bone density for young adult women (T-score at -1 and above) Low bone mass (osteopenia) - BMD between 1-2.5 SD below the mean for young adult women (T-score between -1 and -2.5) Osteoporosis - BMD 2.5 SD or more below the normal mean for young adult females (T-score at or below -2.5) Severe or "established" osteoporosis - BMD 2.5 SD or more below the normal mean for young adult females (T-score at or below -2.5) in a patient who has already experienced 1 or more fractures

The WHO definition applies to postmenopausal women and men aged 50 years or older. Although these definitions are necessary to establish the prevalence of osteoporosis, they should not be used as the sole determinant of treatment decisions. This diagnostic classification should not be applied to premenopausal women, men younger than 50 years, or children.

Whereas the T-score is the bone density compared with the BMD of control subjects who are at their peak BMD, the Z-score reflects a bone density compared with that of patients matched for age and sex.[11, 12, 13, 14]

Z-scores should be used in premenopausal women, men younger than 50 years, and children. Zscores adjusted for ethnicity or race should be used, with Z-scores of -2.0 or lower defined as "below the expected range for age" and those above -2.0 being "within the expected range for age." The diagnosis of osteoporosis in these groups should not be based on densitometric criteria alone. Etiology

Osteoporosis has been divided into several classifications according to etiology and localization in the skeleton. Osteoporosis is initially divided into localized and generalized categories. These 2 main categories are classified further into primary and secondary osteoporosis. Postmenopausal osteoporosis (PMO) is primarily due to estrogen deficiency; senile osteoporosis is primarily due to an aging skeleton and calcium deficiency. Primary osteoporosis

Primary osteoporosis occurs in patients in whom a secondary cause of osteoporosis cannot be identified, including juvenile and idiopathic osteoporosis. Idiopathic osteoporosis can be further subdivided into postmenopausal (type I) and age-associated or senile (type II) osteoporosis, as follows: Juvenile osteoporosis usually occurs in children or young adults of both sexes. These patients have normal gonadal function. The age of onset usually is 8-14 years. The hallmark characteristic of juvenile osteoporosis is abrupt bone pain and/or a fracture following trauma. Type I osteoporosis (postmenopausal osteoporosis) occurs in women aged 50-65 years. This type of osteoporosis is characterized by a phase of accelerated bone loss. This bone loss occurs primarily from trabecular bone. In this phase, fractures of the distal forearm and vertebral bodies are common. Type II osteoporosis (age-associated or senile) occurs in women and men older than 70 years. This form of osteoporosis represents bone loss associated with aging. Fractures occur in cortical and trabecular bone. In addition to wrist and vertebral fractures, hip fractures are often seen in patients with type II osteoporosis. Secondary osteoporosis

Secondary osteoporosis occurs when an underlying disease. have a coexisting cause of bone loss. Up to one third of postmenopausal women.[15. or drug causes osteoporosis. 16] Genetic (congenital) causes of osteoporosis include the following: Cystic fibrosis Ehlers-Danlos syndrome Glycogen storage disease Gaucher disease Hemochromatosis Homocystinuria Hypophosphatasia Idiopathic hypercalciuria Marfan syndrome Menkes steely hair syndrome Osteogenesis imperfecta Porphyria Riley-Day syndrome Hypogonadal states (see below) Hypogonadal states that can cause osteoporosis include the following: Androgen insensitivity Anorexia nervosa/bulimia nervosa Female athlete triad Hyperprolactinemia Panhypopituitarism . deficiency. as well as many men and premenopausal women.

Premature menopause Turner syndrome Klinefelter syndrome Endocrine disorders that can cause osteoporosis include the following[17] : Acromegaly Adrenal insufficiency Cushing syndrome Estrogen deficiency Diabetes mellitus Hyperparathyroidism Hyperthyroidism Hypogonadism Pregnancy Prolactinoma Deficiency states that can cause osteoporosis include the following: Calcium deficiency Magnesium deficiency Protein deficiency Vitamin D deficiency[17. 18] Bariatric surgery Celiac disease Gastrectomy Malabsorption .

barbiturates. carbamazepine (these agents are associated with treatment-induced vitamin D deficiency) Antipsychotic drugs .Malnutrition Parenteral nutrition Primary biliary cirrhosis Inflammatory diseases that can cause osteoporosis include the following: Inflammatory bowel disease Ankylosing spondylitis Rheumatoid arthritis Systemic lupus erythematosus Hematologic and neoplastic disorders that can cause osteoporosis include the following: Hemochromatosis Hemophilia Leukemia Lymphoma Multiple myeloma Sickle cell anemia Systemic mastocytosis Thalassemia Metastatic disease Medications known to cause or accelerate bone loss include the following: Anticonvulsants .Phenytoin.

depomedroxyprogesterone.Prednisone (≥5 mg/d for ≥3 mo)[20] Heparin (long-term) Hormonal/endocrine therapies .Exemestane. ifosfamide.Cyclosporine. platinum compounds.Antiretroviral drugs Aromatase inhibitors . anastrozole Chemotherapeutic/transplant drugs . cyclophosphamide. tacrolimus. excessive thyroid supplementation Lithium Methotrexate Selective serotonin reuptake inhibitors Thyroxine (excessive) Miscellaneous causes of osteoporosis include the following: Alcoholism Amyloidosis Chronic metabolic acidosis Congestive heart failure Depression Emphysema Chronic or end-stage renal disease Chronic liver disease HIV disease/AIDS Idiopathic calciuria .Gonadotropin-releasing hormone (GnRH) agonists. luteinizing hormone-releasing hormone (LHRH) analogs. methotrexate Furosemide Glucocorticoids and corticotropin[19] .

Anticonvulsants. heparin. such as advanced age and reduced bone mineral density (BMD). body weight less than 127 pounds) Amenorrhea Late menarche Early menopause Postmenopausal state Physical inactivity or immobilization[24] Use of drugs . thyroid supplements.Idiopathic scoliosis Immobility Multiple sclerosis Ochronosis Organ transplantation Pregnancy/lactation Sarcoidosis Weightlessness Risk factors Risk factors for osteoporosis. many other factors have been considered risk factors based on their relationship to BMD as a surrogate indicator of osteoporosis. have been established by virtue of their direct and strong relationship to the incidence of fractures. systemic steroids. 23] : Advanced age (50 years or older) Female sex White or Asian ethnicity Genetic factors. insulin . however. such as a family history of osteoporosis Thin build or small stature (eg. Risk factors for osteoporosis include the following[21. chemotherapeutic agents. 22.

statistics from self-reported incidence of fractures in 9449 women and 7436 men in the United States were analyzed. or use of short-acting benzodiazepines. or of osteoporosis.433 women. A longitudinal and prospective cohort study. the authors of the study did agree with other experts that dietary calcium would only help if the patient was calcium deficient. was not further reduced in the highest quintile of calcium intake but was associated with a higher rate of hip fracture. number of children breastfed.[28] Epidemiology United States statistics . concluding that the femoral neck BMD T score and FRAX score were associated with higher hip and nonspine fracture risk in older adult patients with type 2 DM.1 years and found an indirect relationship between the number of risk factors and bone density values. including a subcohort.[26] The study also identified factors that did not increase the risk of fracture. The study concludes that gradual increases in dietary calcium intake did not further reduce fracture risk or osteoporosis in women. The results found that participants with type 2 DM had a higher fracture risk and T score than those without type 2 DM. including hair color. One very interesting finding of this study was that dietary intake of calcium was not correlated to the risk of hip fracture.Alcohol and tobacco use Androgen[25] or estrogen deficiency Calcium deficiency A study by Cummings et al in evaluated 9516 white women aged 65 years for an average of 4. The risk of fractures of any type. prior smoking history. evaluated the effect of dietary calcium on fracture incidence and osteoporosis in 61.[27] One study sought to determine if the femoral neck BMD score and the World Health Organization Fracture Risk Algorithm (FRAX) score are associated with hip and nonspine fracture risk in older adults with type 2 diabetes mellitus (DM). however. Using data from 3 prospective observational studies. The results found that low vitamin D intake was associated with a more pronounced rate of fracture in the first quintile.

which leaves them at increased risk for osteoporosis.to 3-fold higher risk of hip and vertebral fractures (see the images below).[29] Each year in the United States. 300. and Japan have osteoporosis. . The frequency of postmenopausal osteoporosis is highest in women aged 50-70 years. Senile osteoporosis is most common in persons aged 70 years or older. Women and men with metabolic disorders associated with secondary osteoporosis have a 2. Most studies assessing the prevalence and incidence of osteoporosis use the rate of fracture as a marker for the presence of this disorder. Wrist fractures typically occur first. the worldwide incidence of hip fracture is projected to increase by 240% in women and 310% in men. typically at about or after age 50 years.[32] By 2050. 1. as BMD declines.4 for each SD decrease of BMD measurement. as will 1 in 5 men. it speeds up around the time of menopause.000 occur in the spine. Secondary osteoporosis. Another 34 million have low bone mass.[31] One in 3 women older than 50 years will eventually experience osteoporotic fractures. The remainder of fractures occur at other sites in the body. when individuals are aged approximately 50-59 years. Normal femoral anatomy. however. Of these. The number of osteoporotic fractures increases with age. The risk of new vertebral fractures increases by a factor of 2-2.[33] Age distribution for osteoporosis Risk for osteoporosis increases with age.5 million osteoporotic fractures occur.000 occur in the hip. 700. 10 million Americans have osteoporosis. and 200. the United States. Stable intertrochanteric fracture of the femur International statistics Osteoporosis is by far the most common metabolic bone disease in the world and is estimated to affect over 200 million people worldwide.000 occur in the wrist. although BMD also relates to risk of disease and fracture. Although bone loss in women begins slowly. can occur in persons of any age.[30] An estimated 75 million people in Europe.According to the National Osteoporosis Foundation (NOF).

[19] Only 3540% of osteoporosis diagnosed in men is considered primary in nature. 90% of such fractures occur in persons aged 50 years or older. Men have a higher prevalence of secondary osteoporosis. the female-tomale ratio is 5:1. Five percent of nonHispanic black women older than 50 years are estimated to have osteoporosis.[35] Hip fractures occur more often in the eighth decade of life. osteoporosis has a female-to-male ratio of 4:1. . and 35% have low bone mass.Vertebral fractures occur more often in the seventh decade of life. In particular. alcoholism. Racial differences in incidence Osteoporosis can occur in persons of all races and ethnicities. compared with men of the same age. however.[36] Women have a 2-fold increase in the number of fractures resulting from nontraumatic causes. Overall.[36] Sex distribution for osteoporosis Women are at a significantly higher risk for osteoporosis. Twenty percent of non-Hispanic white and Asian women aged 50 years or older are estimated to have osteoporosis. or glucocorticoid excess.[29] Fifty percent of all women and 25% of all men older than 50 years experience an osteoporosisrelated fracture in their lifetime. An estimated one half of all hip fractures will occur in Asia in the next century. In primary osteoporosis. whites (especially of northern European descent) and Asians are at increased risk. Ten percent of Hispanic women aged 50 years or older are estimated to have osteoporosis. with an estimated 4560% being a consequence of hypogonadism. Jensen et al studied Danish women aged 70 years and found a 21% prevalence of vertebral fractures. non-Hispanic white women and Asian women are at higher risk for osteoporosis. Eighty percent of hip fractures occur in women.[34] Melton et al reported that 27% of women in their study had evidence of vertebral fractures by age 65 years. and 49% have low bone mass. and 52% have low bone mass. In general.

and. osteoporotic fractures may lead to chronic pain. Prognosis The prognosis for osteoporosis is good if bone loss is detected in the early phases and proper intervention is undertaken. and diminished quality of life caused by osteoporosis-related fractures. Patients can increase BMD and decrease fracture risk with the appropriate antiosteoporotic medication.9 billion (in 2002 dollars). Three percent of Hispanic men aged 50 years or older have osteoporosis. Women aged 50 years have a 40% lifetime fracture rate as a result of osteoporosis. A study of Japanese American women in Hawaii found a 5% incidence of vertebral fractures each year among individuals aged 80 years. disability. 38.[37. According to a 2004 Surgeon General's report. osteoporosis and other bone diseases are responsible for about 1. Osteoporosis-related fractures result in annual direct care expenditures of $12. Osteoporosis is associated with 80% of all the fractures in people aged 50 years or older.5 million fractures per year.Seven percent of non-Hispanic white and Asian men aged 50 years or older have osteoporosis. regardless of geographic location. Worsening of medical status can be prevented by providing appropriate pain management and. Effect of fractures on prognosis Many individuals experience morbidity associated with the pain. In addition. . in some cases.[41] In 2005. 39] Melton et al reported that the prevalence of hip fractures is higher in white populations. Four percent of non-Hispanic black men aged 50 years or older have osteoporosis.[42] Osteoporosis is the leading cause of fractures in the elderly.2-$17. orthotic devices. If full recovery is not achieved. patients can decrease their risk of falls by participating in a multifaceted approach that includes rehabilitation and environmental modifications. among others. disability. if indicated. and 19% have low bone mass. death. This is particularly true of vertebral and hip fractures.[40] Another study indicated that the incidence of hip fractures was lower among African Americans in the United States and South Africa compared to agematched white populations within the same continent. and 35% have low bone mass. over 2 million osteoporosis-related fractures occurred in the United States. and 23% have low bone mass.

and severe kyphosis was further correlated with pulmonary deaths. In addition. As posture worsens and kyphosis progresses. and early satiety. abdominal pain.[45] Symptoms of vertebral fracture may include back pain. Patients with hip fractures incur decreased independence and a diminished quality of life. More than 250. excess mortality rates can be as high as 20%.[26] Like vertebral fractures. the impact of vertebral fractures increases as they increase in number. patients experience difficulty with balance.[29] Among . while women with 5 or more vertebral fractures had a 2. Lateral radiograph of the patient seen in previous image following kyphoplasty performed at 3 additional levels. back pain. Cooper et al found that vertebral fractures increased the 5-year risk of mortality by 15%. 46] Men have higher mortality rates following hip fracture than do women. Kyphoplasty has been performed at one level. mortality rate was correlated with number of vertebral fractures. height loss. Only one third of people with radiographic vertebral fractures are diagnosed clinically. with 19 per 1000 woman-years in women with no fracture and 44 per 1000 woman-years in women with 5 or more fractures.3-fold increased age-adjusted mortality rate. In one study.[43] In a subsequent study. approximately 20% require long-term nursing care. they are associated with significantly increased morbidity and mortality rates in men and women. Of all patients with hip fracture.23-fold increased age-adjusted mortality rate. and an increased risk of pneumonia. and disabling kyphosis. Kado et al[44] demonstrated that women with one or more fractures had a 1. In the year following hip fracture. Furthermore. Osteoporosis.Vertebral compression fractures (see the images below) are associated with increased morbidity and mortality rates. Lateral radiograph demonstrates multiple osteoporotic vertebral compression fractures. Osteoporosis. Vertebral fractures were related to risk of subsequent cancer and pulmonary death. Compression deformities can lead to restrictive lung disease. and patients may lose their ability to live independently.000 hip fractures are attributed to osteoporosis each year. Overall function declines. respiratory compromise.[43.

and lumbar spine fractures have a 1.[48] Secondary complications of hip fractures include nosocomial infections and pulmonary thromboembolism. the presence of at least one vertebral fracture results in a 5-fold increased risk of developing another vertebral fracture. olecranon.5-. These calculations account for femoral neck bone mineral density (BMD) and other clinical risk factors. and 4. and one third become completely dependent.shef. patients with ankle. WHO fracture-risk algorithm The World Health Organization fracture-risk algorithm (www.ac. 4. coexistence of rheumatoid arthritis) .[50] Patients with previous hip fracture have a 2-fold[51] to 10-fold increased risk of sustaining a second hip fracture.[47] Only one third of patients return to their prefracture level of function. Patients who have sustained one osteoporotic fracture are at increased risk for developing additional osteoporotic fractures.uk/FRAX/) was developed to calculate the 10-year probability of a hip fracture and the 10-year probability of any major osteoporotic fracture (defined as clinical spine. knee. 50% spend time in a nursing home while recovering. hip.[49] For example.1-. One in 5 postmenopausal women with a new vertebral fracture incurs another vertebral fracture within one year. 3. forearm.5-. In addition. Approximately 50% of previously independent individuals become partially dependent.women who sustain a hip fracture. or humerus fracture) in a given patient. as follows[52] : Age Sex Personal history of fracture Low body mass index Use of oral glucocorticoid therapy Secondary osteoporosis (ie.8-fold increased risk of subsequent hip fracture. respectively.

A study by Leslie et al demonstrated the effects of including a patient's 10-year fracture risk along with DXA results in Manitoba. The focus of patient education is on the prevention of osteoporosis. Canada. including increased morbidity and mortality. Many patients are unaware of the serious consequences of osteoporosis. . cessation of smoking. Early prevention and treatment are essential in the appropriate management of osteoporosis. it is important to educate them regarding these consequences. and they should understand the benefits of bone density monitoring. Patients should be educated about the risk factors for osteoporosis. exercise. Patients also need to be educated about the benefits of calcium and vitamin D supplements. Appropriate preventive measures may include adequate calcium and vitamin D intake. All postmenopausal women should be offered bone densitometry.[53] The authors found an overall reduction in dispensation of osteoporosis medications as more women were reclassified into lower fracture risk categories. and moderation of alcohol consumption. accordingly.Parental history of hip fracture Current smoking status Alcohol intake (3 or more drinks per day) The National Osteoporosis Foundation (NOF) recommends osteoporosis treatment in patients with low bone mass in whom a US-adapted WHO 10-year probability of a hip fracture is 3% or more or in whom the risk for a major osteoporosis-related fracture is 20% or more. Society at large also should be educated about the benefits of exercise with regard to osteoporosis. with a special emphasis on family history and the effects of menopause. Prevention has 2 components. behavior modification and pharmacologic interventions. Patient Education Patient education is paramount in the treatment of osteoporosis.[29] Algorithms such as the FRAX algorithm are useful in identifying patients with low bone mass (T-scores in the osteopenic range) who are most likely to benefit from treatment. and only become concerned when osteoporosis manifests in the form of fracture.

and poor health/fragility. alcoholism. estrogen deficiency such as that caused by early menopause (age < 45 y) or bilateral ovariectomy and prolonged premenopausal amenorrhea (>1 y). low body weight (< 127 lb). essential. recurrent falls. Nonmodifiable risk factors include personal history of fracture as an adult. see the following: Osteoporosis and Bone Health Center Eating Disorders Center Esophagus. history of fracture in a first-degree relative. Patients who have not sustained a fracture often do not report symptoms that would alert the clinician to suspect a diagnosis of osteoporosis. The National Osteoporosis Foundation (NOF) has categorized these risk factors into 2 categories: nonmodifiable and modifiable. Multiple risk factors exist for osteoporosis. Screening at-risk populations is. This disease is a "silent thief" that generally does not become clinically apparent until a fracture occurs. advanced age. therefore. and Intestine Center Women's Health Center Osteoporosis Anorexia Nervosa Inflammatory Bowel Disease Menopause Hormone Replacement and Osteoporosis History Osteoporosis is typically asymptomatic until a fracture occurs.For patient education resources. and poor health or frailty. female sex. dementia. Potentially modifiable risk factors include current cigarette smoking. low lifelong calcium intake. inadequate physical activity. white race. Stomach. .[54] impaired eyesight despite adequate correction.

particularly maternal history of fractures Reproductive factors.Smokers are at higher risk Alcohol consumption Low levels of physical activity . Specifically. especially regarding early menopause and estrogen replacement therapy Postmenopausal women are at high risk. orthostatic hypotension. and cognitive impairment Patients with acute insufficiency fractures may report a history of minimal or no trauma resulting in pain.These include poor balance. They may report a fall from a standing or sitting position. weakness of the lower extremity muscles and deconditioning. use of medications with sedative effects. as are women who have undergone hysterectomy and oophorectomy Hypogonadal states .Men with hypogonadism secondary to any genetic or other conditions are at higher risk Smoking . sex (female).A thorough history should be obtained to screen for and identify the presence of known risk factors for osteoporosis and osteoporotic fracture. poor vision or hearing.Immobility increases the risk[24] . and race (white or Asian) Family history of osteoporosis. spinal cord injury and stroke cause physical impairment and are common causes of immobility Strenuous exercise (such as occurs in marathon runners) that results in amenorrhea Calcium and vitamin D intake History of low-trauma "fragility" fracture in patients aged 40 years or older . the history should focus on the following[55] : Age (>50 years).A fragility fracture is defined as a fracture due to trauma that would not normally cause fracture (a force equal to or less than that resulting from a fall from standing height) Signs of vertebral fracture (see below) Coexisting medical conditions associated with bone loss (see Etiology) Medications associated with bone loss (see Etiology) Risk factors for falls in older patients . Patients with compression fractures resulting in thoracic kyphosis may report iliocostal friction with associated abdominal .

Patients with hip. decreased tolerance for oral intake.protrusion. identifiable. In some cases. It should be noted. or dull. pelvic. posterior buttock. . movement may exacerbate pain. or sacral fractures may report pain that is worsened with weightbearing. particularly internal rotation and flexion Patients may have external rotation of the involved hip while in the resting position Patients with osteoporosis may report lactose intolerance and celiac sprue. With respect to those vertebral fractures that are painful. Patients who have sustained a vertebral compression fracture may note progressive kyphosis with loss of height. In the setting of multiple fractures with severe kyphosis. They may also present with an episode of acute back pain after bending. Celiac sprue has been shown to be associated with osteoporosis in approximately 5% of cases. that two thirds of vertebral fractures are asymptomatic. medial thigh. and breathing difficulties. lifting. or coughing. pain radiates to the abdomen Pain is often accompanied by paravertebral muscle spasms exacerbated by activity and decreased by lying supine Patients often remain motionless in bed because of fear of causing an exacerbation of pain Acute pain usually resolves after 4-6 weeks. however. and/or medial knee during weightbearing or attempted weightbearing of the involved extremity Diminished hip range of motion (ROM) is reported. anterior thigh. the pain may become chronic Patients who have sustained a hip fracture may experience the following: Patients may have pain in the groin. typical subjective information may include the following: The episode of acute pain may follow a fall or minor trauma Pain is localized to a specific. vertebral level in the midthoracic to lower thoracic or upper lumbar spine The pain is described variably as sharp. nagging.

hip. . poor vision or hearing. The examination may elicit pain. orthostatic hypotension. or the patient may be pain free. the patient's height may decrease by 2-3 cm. wrist. lower-extremity weakness. point tenderness over a vertebrae or other suspected fracture site) Signs suggestive of secondary osteoporosis Signs in older patients that may indicate increased fall risk (eg. The physical examination should begin with an inspection of the patient. Examination of active and passive range of motion (ROM) assists in determining whether spine. Height measurement with a stadiometer at each visit is useful. Areas of concern include the following: A history of loss of height Low body weight (body mass index < 19 kg/m2) Signs that might indicate existing osteoporosis (eg. cognitive impairment) Signs of fracture Patients with vertebral compression fractures may demonstrate a thoracic kyphosis with an exaggerated cervical lordosis (dowager's hump). Thoracic kyphosis may be present secondary to vertebral compression fractures. After each episode of vertebral compression fracture and progressive kyphosis. or other osseous pathology may be present. difficulty with balance or gait. and a history of loss of height.Physical Examination Patients with suspected osteoporosis should undergo a comprehensive physical examination. Patients may have an associated scoliosis. a dowager hump. A thorough neurologic examination is essential to rule out spinal cord and/or peripheral nerve compromise. kyphosis or dowager's hump. This is followed by a loss of lumbar lordosis.

vertebrae. or squish test. Patients with pubic and sacral fractures may report marked pain with ambulation and tenderness to palpation.[26] . A flexion in abduction and external rotation (faber) hip joint test may reveal limited ROM with end-range pain. dentinogenesis imperfecta. patients with sacral fractures may have pain with physical examination techniques used to assess the sacroiliac joint. Palpation of the spinous processes often does not aid the examiner in localizing point tenderness. but percussion may be helpful in acute or subacute vertebral compression fractures. or both. such as the faber. hearing loss. are typically painful and result in limited range of motion of the involved joint. Poor balance may be noted particularly in patients with severe kyphosis resulting from vertebral compression fractures because their altered center of gravity makes ambulation with a stable base of support difficult for them. Patients may have difficulty performing tandem gait and performing single limb stance. Gaenslen. possibly secondary to differences in balance control strategies and sway amplitude. Patients with hip fractures may have severe pain with ambulation. pes planus. Signs of collagen defects Patients with osteoporosis may have physical findings consistent with subtle collagen defects.[56] Fractures are the most common and serious complication of osteoporosis. Balance difficulties Patients with osteoporosis are known to have decreased balance. ribs. and wrists. Furthermore. hyperlaxity. These include a short fifth digit. bunions.Patients with acute vertebral fractures may have point tenderness over the involved vertebrae. Fractures in other parts of the body. Patients with osteoporosis are at high risk for recurrent fractures of the hips. and blue sclerae. including the distal radius and humerus. Patients with hip fractures may show decreased weightbearing on the fractured side or an antalgic gait pattern. percussion.

Hip fractures are the most devastating and occur most commonly at the femoral neck and intertrochanteric regions. The likelihood of sustaining a hip fracture during a fall is related to the direction of the fall. . or bending. These patients can lose their self-esteem and are at increased risk for depression. lifting. Fractures are more likely to occur in falls to the side. Patients with osteoporosis develop spinal deformities and a dowager's hump. always rule out the other possible causes of symptoms before treating the patient for osteoporosis. less subcutaneous tissue is available to dissipate the impact. Many patients have a coexisting cause of bone loss. This should be investigated and treated. vertebral fracture can occur slowly and without symptoms. Secondary complications of hip fractures include nosocomial infections and pulmonary thromboembolism.[57] They are also at risk for all the complications of immobility. Diagnostic Considerations The differential diagnosis of osteoporosis is very extensive and includes all the secondary causes. such as coughing. including chronic pain from vertebral compression fractures and increased morbidity and mortality secondary to vertebral compression fractures and hip fractures.Complications Vertebral compression fractures often occur with minimal stress. In many patients. Patients with multiple fractures have significant pain. Respiratory compromise can occur in patients with multiple vertebral fractures that result in severe kyphosis. which leads to functional decline and a poor quality of life (QOL). The vertebrae of the middle and lower thoracic spine and upper lumbar spine are involved most frequently. Hip fractures are associated with falls. Fractures can cause further complications. including deep vein thrombosis (DVT) and pressure ulcers. When dealing with reduced bone density. and they may lose 1-2 inches of height by their seventh decade of life.

and other bone-softening metabolic disorders. In osteoporosis. whereas in osteomalacia. the bones are porous and brittle. This difference in bone consistency is related to the mineral-to-organic material ratio. infection. osteonecrosis. but in osteoporosis. while in osteomalacia the bones are soft. Failure to diagnose and/or make appropriate referrals may create potential legal issues. Osteoporosis may be confused with osteomalacia. Metastatic bone disease should always be ruled out when one is treating multiple fractures. tumor. The presence of a fracture often is not only a marker for decreased bone mass but also potentially a symptom of failing health in general and 1 or more primary disorders in particular.The differential diagnosis of an atraumatic compression fracture may include osteomalacia. the mineral-to-collagen ratio is within the reference range. the proportion of mineral composition is reduced relative to organic mineral content. Other conditions to be considered include the following: Homocystinuria Leukemia Lymphoma Mastocytosis Metastases (bony and other) Pathologic fractures secondary to bone metastases from cancer Pediatric osteogenesis imperfecta Renal osteodystrophy Scurvy Sickle cell anemia Differentials Hyperparathyroidism Multiple Myeloma .

phosphate. Alkaline phosphatase.[58] Inadequate vitamin D levels can predispose persons to osteoporosis. therefore. Severe hypercalcemia may reflect underlying malignancy or hyperparathyroidism. liver function tests. phosphate. Lab Studies The following laboratory studies are used to establish baseline conditions or to exclude secondary causes of osteoporosis: Complete blood count (CBC) Serum chemistries. In addition. Thyroid dysfunction has been associated with osteoporosis and should. be ruled out. Bone biopsy may be indicated in specific situations. .Osteomalacia and Renal Osteodystrophy Paget Disease Approach Considerations Workup consists of appropriate laboratory studies to establish baseline values and look for potential secondary causes of osteoporosis. electrolytes Thyroid-stimulating hormone (TSH) level 25-Hydroxyvitamin D level Calcium levels can reflect underlying disease states. creatinine. hypocalcemia can contribute to osteoporosis. including calcium. along with measurement of bone mineral density (BMD) to assess bone loss and estimate the risk of fracture. and 25(OH) vitamin D levels may be obtained to assist in the diagnosis of osteomalacia. calcium. phosphate. and alkaline phosphatase are usually normal in persons with primary osteoporosis. although alkaline phosphatase levels may be elevated for several months after a fracture. Levels of serum calcium.

urine N-methylhistamine for mastocytosis Bone marrow biopsy if a hematologic disorder is suspected Twenty-four-hour urinary calcium levels help to rule out benign familial hypocalciuric hypercalcemia (FHH). one study showed reduced femoral neck bone mineral density (BMD) in women with subclinical hypothyroidism and hyperthyroidism. . An elevated PTH level may be present in benign familial hypocalciuric hypercalcemia (FHH). a testosterone profile and gonadotropin value should be obtained.Other laboratory studies used to evaluate for secondary causes include the following: Twenty-four-hour urine calcium to assess for hypercalciuria Intact PTH level Thyrotropin (if on thyroid replacement) level Testosterone and gonadotropin levels Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) value Urinary free cortisol and tests for adrenal hypersecretion Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) Antigliadin and antiendomysial antibodies for celiac disease Serum tryptase. however. Experts are divided on whether to include thyrotropin testing. In younger men with low bone densities. Some practitioners include ESR and CRP values in the workup. in which urinary calcium levels are low. regardless of a history of thyroid disease or replacement. An intact PTH level is essential in ruling out hyperparathyroidism. although their utility in this setting has not been proven in an evidence-based manner.

when present. Serum iron and ferritin values are helpful if malabsorption or hemochromatosis is suspected. minimal laboratory screening is indicated in all patients who present with decreased bone mass. particularly those older than 60 years. Patients with anemia. which has been associated with approximately 5% of osteoporosis cases. A history of loose stools with anemia should raise the possibility of celiac sprue. a urine free cortisol value or overnight dexamethasone suppression testing should be ordered if Cushing syndrome is suspected. Currently available serum markers of bone formation (osteoblast products) include the following: Bone-specific alkaline phosphatase (BSAP) Osteocalcin (OC) Carboxyterminal propeptide of type I collagen (PICP) Aminoterminal propeptide of type I collagen (PINP) . SPEP may be performed to rule out plasma cell dyscrasias. early postmenopausal osteoporosis) and may be useful in some patients for monitoring early response to therapy.SPEP and UPEP are used to exclude the presence of multiple myeloma. should also be evaluated for multiple myeloma with a serum and urine protein electrophoresis. Specialized laboratory testing is guided by clinical suspicion or initial screening test results. leads to rapidly progressive osteoporosis. Biochemical Markers of Bone Turnover Biochemical markers of bone turnover reflect bone formation or bone resorption. Given that occult disorders are so common among patients with osteoporosis. An important study by Tannenbaum[59] evaluated 173 healthy women (ages 46-87 y) for secondary causes of osteoporosis and found that 55 (32%) had a previously undiagnosed disorder of bone or mineral metabolism. These markers (both formation and resorption) may be elevated in high-bone-turnover states (eg. Cushing syndrome is not common but.

At the primary author's institution. In addition. urinary NTx. indicate a high-turnover type of osteoporosis. OC. if high. and serum CTx. Significant controversy exists regarding the use of these biochemical markers. Paget disease. a urine NTx value normalized to creatinine excretion from the second urination of the day is used primarily to identify osteopenic patients in a high-turnover state who would benefit from therapy . BSAP can be mildly elevated in patients with fractures. and concerns have been raised about intra-assay and interassay variability. Serum OC levels. or osteomalacia can have elevations of BSAP. patients with hyperparathyroidism.[60] Elevation of urinary NTx (>40 nmol bone collagen equivalent per mmol urinary creatine) indicates a high turnover state. the ones most commonly used in clinical practice are BSAP.Currently available urinary markers of bone resorption (osteoclast products) include the following: Hydroxyproline Free and total pyridinolines (Pyd) Free and total deoxypyridinolines (Dpd) N-telopeptide of collagen cross-links (NTx) C-telopeptide of collagen cross-links (CTx) Currently available serum markers of bone resorption include the following: Cross-linked C-telopeptide of type I collagen (ICTP) Tartrate-resistant acid phosphatase NTx CTx Of the aforementioned tests. NTx levels may also be used to monitor responses to antiosteoporotic treatments.

Approximately 30-80% of bone mineral must be lost before radiographic lucency becomes apparent on radiographs. Radiographic findings can suggest the presence of osteopenia. Because osteoporosis predominantly affects trabecular rather than cortical bone.and to monitor the response to therapy in all patients. or bone loss. BMD has been shown to be the best indicator of fracture risk. However. plain radiography may be indicated if a fracture is already suspected or if patients have lost more than 1. 63] . Plain Radiography Plain radiography is recommended to assess overall skeletal integrity. Obtain radiographs of the affected area in symptomatic patients. the sum of the cortical width should be at least equal to the medullary width. A scoliosis series is useful for detecting occult vertebral fractures. Lateral spine radiography can be performed in asymptomatic patients in whom a vertebral fracture is suspected.[62.[61] Thus. in those with height loss in the absence of other symptoms. further study is needed to determine the clinical utility of these markers in osteoporosis management. although they cannot be used to diagnose osteoporosis. Osteopenia is suggested by a sum that is less than the medullary width. Radiographs may also show fractures or other conditions such as osteoarthritis. In particular. Cortical bone is not affected by osteoporosis until more than 30% bone loss has occurred. Dual-Energy X-Ray Absorptiometry Several large prospective studies have shown that BMD measurements of the distal and proximal femur and the vertebral bodies can predict the development of the major types of osteoporotic fractures. According to the National Osteoporosis Foundation (NOF). in the workup for osteoporosis. disc disease. or spondylolisthesis. plain radiography is an insensitive tool for diagnosing osteoporosis. evaluating BMD on a periodic basis is the best way to monitor bone mass and future fracture risk.5 inches of height. Plain radiography is not as accurate as BMD testing. Using the second metacarpal or the metaphysis of a long bone. or in those with pain in the thoracic or upper lumbar spine. radiography does not reveal osteoporotic changes until they affect the cortical bone.

rheumatoid arthritis) or who take a medication (eg. current evidence is insufficient to assess the balance of benefits and harms of screening.The NOF and the International Society for Clinical Densitometry (ISCD) recommend that BMD be measured in the following patients: Women aged 65 years and older and men aged 70 years or older. the USPSTF makes no recommendation for screening men without risk factors. in contradiction to the NOF recommendation. regardless of clinical risk factors Younger postmenopausal women and men aged 50-70 years with clinical risk factors for fracture Women in menopausal transition with a specific risk factor associated with increased risk for fracture (ie. .[64] The USPSTF recommends measuring BMD in the following patients: Women aged 65 years and older without previous known fractures or secondary causes of osteoporosis Women younger than 65 years whose 10-year fracture risk is equal to or greater than that of a 65-year-old white woman without additional risk factors These recommendations do not contradict the NOF recommendations for screening in women. glucocorticoids. use of a high-risk medication) Adults with fragility fractures Adults who have a condition (eg. For men without previous known fractures or secondary causes of osteoporosis. ≥ 5 mg of prednisone daily for ≥ 3 mo) associated with low bone mass or bone loss Anyone being considered for pharmacologic therapy for osteoporosis Anyone being treated for osteoporosis (to monitor treatment effect) Anyone not receiving therapy in whom evidence of bone loss would lead to treatment The US Preventive Services Task Force (USPSTF) has issued updated recommendations on screening for osteoporosis. low body weight. prior low-trauma fracture. However.

Imaging options include densitometry. The sensitivity. single-photon absorptiometry (SPA). and singlephoton emission CT (SPECT) scanning. calcaneus Spine. forearm. quantitative computed tomography (QCT) scanning. examination time. and radiation exposure of the different imaging techniques differ greatly (see the table below). hip. . Comparison of Densitometry (Open Table in a new window) Single-Photon Absorptiometry Dual-Photon Absorptiometry Dual-Energy X-Ray Absorptiometry Quantitative Computed Tomography Time 5-15 min Cost $50-150 20-30 min $150-300 5-10 min $100-200 10-30 min $150-300 Sites Scanned Radius. Table. magnetic resonance imaging (MRI). hip (anteroposterior) Spine (lateral). bone scanning. hip. radius Spine (lateral). cost. dual-photon absorptiometry (DPA). dual-energy x-ray absorptiometry (DEXA).

[62. dye injection) for performing it. This method can be used in both adults and children. Radiation exposure is kept to a minimum. It is done on an outpatient basis. lower costs. 65] It is not as sensitive as QCT scanning for detecting early trabecular bone loss. and greater precision. but it provides rapid scanning times. This improvement results in more accurate measurements of trabecular BMD and greater sensitivity for detecting osteoporosis. When available. Factors that may . the same technologist should perform subsequent measurements on the same patient using the same machine. Whenever possible.[63] and there are no special requirements (eg. DEXA is currently the criterion standard for the evaluation of BMD. hip. it may be most useful in identifying patients at very low fracture risk who require no further workup. VFA should be considered when the results may influence clinical management of the patient.radius Out of all these imaging options. Vertebral fracture assessment (VFA) is not available with all DEXA machines. thus eliminating measurement of the cortical-rich structures. DEXA is used to calculate BMD at the lumbar spine. This resulted in measurements of not only the trabecular-rich vertebral bodies but also the corticalrich spinal elements.[66] Peripheral DEXA is used to measure BMD at the wrist. First-generation DEXA scanners measured spinal BMD in just the anteroposterior view. Although measurement or BMD at any site can be used to assess overall fracture risk. New-generation scanners are capable of measuring spinal BMD in the lateral view. Densitometric spine imaging can be performed at the time of DEXA scanning to detect vertebral fractures. and proximal femur. measurement at a particular site is the best predictor of fracture risk at that site.

whereas the Z-score reflects a value compared to patients matched for age and sex.5 SD indicates osteopenia T-score of less than -2.0 SD or lower defined as "below the expected range for age" and those above -2. and artifacts caused by vascular calcifications. Values lying farther from the mean are stratified as follows: T-score of -1 to -2. osteophytosis.0 SD being "within the expected range for age. but its use is limited by poor reproducibility. men younger than 50 years. but it is relatively insensitive for detecting early-stage osteoporosis because it measures cortical rather than trabecular bone. aortic) calcification. 14] World Health Organization (WHO) criteria define a normal T-score value as within 1 standard deviation (SD) of the mean BMD value in a healthy young adult.5-3 times. and extraspinal (eg. with values of -2." The diagnosis of osteoporosis in these groups should not be based on densitometric criteria alone. DPA can measure BMD in the spine and proximal femur. Instead. Single.[11. This diagnostic classification should not be applied to premenopausal women. or children. the relative fracture risk is increased 1. Z-scores adjusted for ethnicity or race should be used. Quantitative Computed Tomography Scanning .5 SD with fragility fracture(s) indicates severe osteoporosis For each SD reduction in BMD.and Dual-Photon Absorptiometry SPA of the proximal forearm provides precision and offers low radiation exposure. 13. Bone density data from a DXA are reported as T-scores and Z-scores. 12.result in a falsely high BMD determination include spinal fractures. prolonged scanning times.5 SD indicates osteoporosis T-score of less than -2. The T-score is the value compared to control subjects who are at their peak BMD.

QCT is more expensive. which is not influenced by bone size. QCT scanning is seldom used now. Using fat suppression sequences. marrow edema consistent with fracture may be noted as areas of hypointensity on T1-weighted images in association with corresponding areas of hyperintensity on T2-weighted images. MRI can be used to discriminate between acute and chronic fractures of the vertebrae and occult stress fractures of the proximal femur. These osteoporotic fractures demonstrate characteristic changes in the bone marrow that distinguish them from other uninvolved parts of the skeleton and the adjacent vertebrae. This technique can be used in both adults and children but assesses BMD only at the spine. nor can it be used to monitor the response to treatment. MRI is a very sensitive modality and is believed by some to be the first diagnostic imaging method of choice in the detection of acute fractures. It may also be used for evaluation of metastatic bone disease.QCT scanning is another method employed to measure spinal BMD. QCT scanning of the spine is the most sensitive method for diagnosing osteoporosis because it measures trabecular bone within the vertebral body. because of its lack of precision. QCT scanning may be useful in identifying fractures. It has the advantage of not involving radiation. It can be used to identify not only the fracture line but also areas of callus formation and sclerosis. In addition. It is not an ideal technique when repeated measurements are needed to detect small changes in BMD. it is subject to possible interference by osteophytes. and requires a higher radiation dose. . Magnetic Resonance Imaging MRI may be useful in identifying fractures. Ultrasonography cannot be used for monitoring skeletal changes over time. Consequently. consistent with healing fracture. Ultrasonography Quantitative ultrasonography of the calcaneus is a low-cost portable screening tool. such as sacral fractures. has relatively poor reproducibility. but it is not as accurate as other imaging methods. It measures BMD as a true volume density in g/cm3. Compared with DEXA scanning.

Images may be obtained in 3 phases of the bone scanning process. separating vertebral body. or osteomalacia is suspected. facet and pars interarticularis lesions).MRI can be useful in the assessment of metabolic bone disease. Bone Scanning Bone scanning assesses the function and tissue metabolism of organs by using a radionuclide (technetium-99m) that emits radiation in proportion to its attachment to a target structure. This localization is possible because SPECT can visualize bony structures that would overlap on planar images (eg. It increases the sensitivity and specificity of bone scanning for detection of lumbar spine lesions by 20-50% over planar techniques. the immediate static blood pool study. Bone biopsy can help to exclude underlying pathologic conditions such as multiple myeloma. Acute fractures are visible in all phases of bone scanning and may remain beyond the reference range for up to 2 years. It is a nonspecific modality. SPECT scanning is helpful when accurate localization of skeletal lesions within large and/or anatomically complex bony structures is required. therapy is not eliciting a response. but it is very sensitive for detecting bony abnormalities because an increase in osteoblastic activity (as seen in compression fractures) results in an increase of the radionuclide tracer concentration. Single-Photon Emission CT Scanning SPECT scanning represents a tomographic (CT-like) bone imaging technique that offers better image contrast and more accurate lesion localization than planar bone scanning. These phases are the immediate-flow study. which may be responsible for presumed osteoporotic fracture. Biopsy Undecalcified iliac bone biopsy with double tetracycline labeling is rarely necessary but may be considered when no cause for osteoporosis is apparent. . and the delayed static study.

this appears on a biopsy sample as a second line of fluorescence. Lateral radiograph demonstrates multiple osteoporotic vertebral compression fractures.BMD within 1 standard deviation (SD) of the mean bone density for young adult women (T-score at -1 and above) . Histologic Findings Although bone biopsy is rarely needed to rule out neoplasms and other metabolic bone diseases. which binds to newly formed bone. Histologic examination of osteoporotic bone may reveal generalized thinning of trabeculae and irregular perforation of trabeculae. Lateral radiograph of the patient seen in previous image following kyphoplasty performed at 3 additional levels. A second dose of tetracycline is given 11-14 days after the first dose. it is sometimes used to quantitate bone loss. Kyphoplasty has been performed at one level. subsequently.[36] WHO Definition of Osteoporosis Bone mineral density (BMD) in a patient is related to peak bone mass and. iliac crest biopsy is performed either in the minor procedure suite or in the operating room. The distance between the 2 fluorescent labels can be measured to calculate the amount of bone formed during that interval. bone loss. Osteoporosis. Tetracycline double labeling is a process used to calculate data on bone turnover. reflecting unbalanced osteoclast-mediated bone resorption. The World Health Organization (WHO) has established the following definitions of osteoporosis based on BMD measurements in white women: Normal . In this procedure. This appears on biopsy samples as linear fluorescence. Osteoporosis. patients are given tetracycline. One may also perform a vertebral body bone biopsy when performing a therapeutic procedure such as kyphoplasty (see images below) or vertebroplasty for fixation of a vertebral compression fracture.Typically. using quantitative histomorphometric techniques.

Zscores adjusted for ethnicity or race should be used. with Z-scores of -2.5) Osteoporosis . 12.BMD 2.5) Severe or "established" osteoporosis . potentially treatable underlying causes of osteoporosis such as hyperparathyroidism and hyperthyroidism should be ruled out or treated if detected.BMD between 1-2.5 SD or more below the normal mean for young adult females (T-score at or below -2.5 SD or more below the normal mean for young adult females (T-score at or below -2.0 being "within the expected range for age." The diagnosis of osteoporosis in these groups should not be based on densitometric criteria alone. vitamin D. or children. and antiosteoporotic medication such as bisphosphonates[67] and parathyroid hormone (PTH).5 SD below the mean for young adult women (T-score between -1 and -2. the Z-score reflects a bone density compared with that of patients matched for age and sex. they should not be used as the sole determinant of treatment decisions. 13. Whereas the T-score is the bone density compared with the BMD of control subjects who are at their peak BMD. men younger than 50 years.0 or lower defined as "below the expected range for age" and those above -2. This diagnostic classification should not be applied to premenopausal women.5) in a patient who has already experienced 1 or more fractures The WHO definition applies to postmenopausal women and men aged 50 years or older. 14] Z-scores should be used in premenopausal women. and children.BMD 2. Although these definitions are necessary to establish the prevalence of osteoporosis. . In addition.[11.Low bone mass (osteopenia) . men younger than 50 years. Approach Considerations Medical care includes the administration of adequate calcium.

Counsel patients to avoid tobacco use. Identify and treat alcoholism. The authors concluded that multicomponent tools aimed at doctors and patients may support clinical decision making in the management of osteoporosis. and exercise.[68] In addition.[2] Medical Care Currently. Early intervention can prevent osteoporosis in most people. A 2008 literature review suggested that the use of "reminders plus education targeted to physicians and patients" can lead to increased bone mineral density (BMD) testing and greater use of osteoporosis medications. treatment for the primary disorder should be provided. and supplementing with calcium and vitamin D. If secondary osteoporosis is present. A 2009 study indicated that the use of a case manager for the treatment of patients with hip fractures can. including adequate calcium intake. vitamin D intake. in comparison with a more commonly employed care strategy. discontinuing the drug as soon as possible. Protective measures should be taken in patients who must take glucocorticoids for other medical conditions. Patients identified as at risk for osteoporosis (including children and adolescents) should undergo preventive measures. . increased life expectancy. and significant health-care cost savings. can lead to more frequent use of appropriate osteoporosis treatment and may result in fewer fractures.Surgical care includes vertebroplasty and kyphoplasty. For patients with established osteoporosis. no treatment can completely reverse established osteoporosis. Vertebroplasty and kyphoplasty are minimally invasive spine procedures used for the management of painful osteoporotic vertebral compression fractures. a physician reminder in conjunction with a patient risk assessment strategy apparently can result in a reduction in patient fractures and an increase in osteoporosis therapy. medical intervention can halt its progression. These include using the minimum effective dose.

or spine) T-score less than -2. or spine) and (1) 10-year probability of hip fracture of 3% or more or (2) a 10-year probability of any major osteoporosis-related fracture of 20% or more based on the US-adapted World Health Organization (WHO) algorithm[52] The American College of Physicians has reviewed the evidence and has proposed guidelines for pharmacologic treatments of osteoporosis. calcitonin. The second includes medications that reduce bone resorption. total hip.The National Osteoporosis Foundation (NOF) recommends that pharmacologic therapy should be reserved for postmenopausal women and men aged 50 years or older who present with the following: A hip or vertebral fracture (Vertebral fracture may clinical or morphometric [ie. the selective estrogen-receptor modulator (SERM) raloxifene. such as estrogen. calcitonin. These medications may be classified into 2 primary categories. bisphosphonates. such as vitamin D and bisphosphonates. 71] All therapies should be given with calcium and vitamin D supplementation.5 at the femoral neck.0 and -2. calcium.) Other prior fractures and low bone mass (T-score between -1.5 at the femoral neck.[69] The agents currently available for osteoporosis treatment include bisphosphonates.[72] Guidelines from the American Association of Clinical Endocrinologists (AACE). The first includes medications that help to stimulate bone formation.5 at the femoral neck. identified on a radiograph alone]. denosumab. glucocorticoid use or total immobilization) Low bone mass (T-score between -1.0 and -2. 70. teriparatide (human recombinant PTH 1-34). total hip. published in 2010. include the following recommendations for choosing drugs to treat osteoporosis[73] : .0 and -2. and one anabolic agent. or spine after appropriate evaluation to exclude secondary causes Low bone mass (T-score between -1. or spine) and secondary causes associated with high risk of fracture (eg.5 at the femoral neck. total hip. and vitamin D. total hip.[19.

1500 mg/d Age 65 years and older .1200-1500 mg/d Age 25 to 50 years .Calcitonin Treatment for patients with very high fracture risk or in whom bisphosphonate therapy has failed .400 mg/d Age 6 months to 1 year .Raloxifene Last-line agent .500 mg/d Age 4 to 8 years .Alendronate.800-1200 mg/d Age 11 to 24 years .or third-line agent .1200-1500 mg/d Current recommendations from the National Osteoporosis Foundation for daily calcium intake are as follows: Age 1 to 3 years .First-line agents .1000 mg/d Age 51 to 64 years .Ibandronate Second. denosumab Second-line agent .800 mg/d .600 mg/d Age 1 to 10 years . zoledronic acid.1000 mg/d Age 51 years and older (only women not on hormone replacement therapy [HRT]) .1500 mg/d Pregnant or lactating women .Teriparatide The AACE guidelines advise against the use of combination therapy. risedronate. Calcium and vitamin D supplementation The goal of the current recommendations for daily calcium intake is to ensure that individuals maintain an adequate calcium balance. the National Institutes of Health recommended the following daily calcium intake: Birth to age 6 months . In 1994.

[74] A meta-analysis of 12 double-blind. and a higher dose reduced fractures by at least 20% in individuals aged 65 years or older. An increased risk for myocardial infarction was associated with patients taking calcium supplements. when administered with calcium.1300 mg /d Age 19 to 49 years . Several large studies have demonstrated that supplementation with a combination of calcium and vitamin D can reduce fracture risk.1200 mg/d Pregnant and breastfeeding women age 18 years and younger . although. The minimum daily requirement in patients with osteoporosis is 800 IU of vitamin D3.[76] The conclusions were based on 7 large studies that were randomized with at least one intervention arm in which vitamin D was given and included analysis of fractures as an outcome and at least 1000 participants. or cholecalciferol.Age 9 to 18 years .[77] This increased risk has not been associated with dietary calcium intake. to be considered vitamin D replete.[75] An additional meta-analysis concluded that vitamin D alone is not effective in preventing fractures. continuously or for a short period. hip fractures and total fractures (and possibly vertebral fractures) were reduced. defined as a serum 25-hydroxyvitamin D level of 32 ng/mL. randomized. Many patients require more. controlled trials of nonvertebral fractures and 8 randomized controlled trials of hip fractures comparing oral vitamin D (with or without calcium) with either calcium alone or placebo showed that nonvertebral fracture prevention with vitamin D is dose-dependent. Bolland et al conducted a meta-analysis of patients taking calcium supplements (without coadministered vitamin D) and association with cardiovascular risks.1000 mg/d Age 50 years and older . .1000 mg/d Vitamin D is increasingly being recognized as a key element in overall bone health and muscle function.1300 mg/d Pregnant and breastfeeding women age 19 years and older . More information is needed regarding risks associated with long-term calcium supplementation.

hip fractures by 41%. decreases bone strength and resilience. given weekly or monthly. given orally once a month. biopsy specimens of these individuals have suggested extremely low turnover states. Some limited reports. to be taken sitting upright with a large glass of water at least 30 minutes before eating in the morning. at very high levels in animals.Bisphosphonates Bisphosphonates are the most commonly used agents for osteoporosis. and ibandronate. national register–based.[80] . Zoledronic acid is the most potent bisphosphonate available. It increases BMD at the spine by 4.5% compared with placebo. Intravenous bisphosphonates are excellent choices for patients intolerant of oral bisphosphonates or in those in whom adherence is an issue. bisphosphonate therapy decreases bone turnover and. It reduces the incidence of spine fractures by 70%. They have been employed for both treatment and prevention.[78] Other oral bisphosphonates include risedronate. The results of a populationbased. Zoledronic acid is once-yearly intravenous infusion approved for the treatment of postmenopausal osteoporosis. Ibandronate is available as an intravenous formulation that is given every 3 months. and nonvertebral fractures by 25% over 3 years. Ibandronate has not shown efficacy in nonvertebral fractures in the clinical trials. Well-conducted controlled clinical trials using alendronate sodium indicate that treatment reduces the rate of fracture at the spine. describe patients on long-term bisphosphonate therapy developing transverse stress fractures.) Oral and intravenous (IV) options are available. including that by Odvina et al.[79] Over time. and wrist by 50% in patients with osteoporosis. hip.3-5. (See Prevention of Osteoporosis. Risedronate reduced vertebral fractures by 41% and nonvertebral fractures by 39% over 3 years.088 patients suggest that elderly patients who use proton pump inhibitors in conjunction with alendronate have a dose-dependent loss of protection against hip fracture.1-3. open cohort study of 38. The treatment dose of alendronate is 70 mg/wk. Alendronate has been shown to increase spinal and hip mineral density in postmenopausal women.1% and the hip by 3.

A Canadian study by Park-Willie et al found the estimated absolute risk of a subtrochanteric or femoral shaft fracture among 52.[73] Raloxifene SERMs are considered to provide the beneficial effects of estrogen without the potentially adverse outcomes.22% within 2 years). in some patients. and data in females with osteoporosis have demonstrated that raloxifene causes a 35% reduction in the risk of vertebral fractures.13% during the subsequent year and 0. 20-40). while the bisphosphonates are outstanding in their efficacy. bone turnover markers should be monitored. a drug holiday of 1-2 years may be considered after 10 years of treatment. Some studies have sought to clarify the true risks of complications in patients receiving bisphosphonates. the patient should be taken off the bisphosphonates and given a rest period until he or she can return to therapeutic levels (Ntelopeptide of collagen cross-links [NTx]. especially those with a lower risk of fracture. The limited trial data available on long-term treatment with bisphosphonates has raised questions about the optimal length of treatment with these medications.[83] The AACE recommends that clinicians consider a ―drug holiday‖ after 4-5 years of bisphosphonate treatment. a SERM first studied for breast cancer prevention. bisphosphonate treatment may be stopped.[81] This issue has become more important given newly recognized complications of bisphosphonate use. It has been shown to prevent bone loss. and treatment should be restarted if density declines substantially. if fracture risk is high. if these become profoundly suppressed. a patient’s risk of fracture can be used to help guide length of treatment.595 women with at least 5 years of bisphosphonate therapy to be low (0. It has also been shown to reduce the prevalence of invasive breast cancer. including osteonecrosis of the jaw and atypical (subtrochanteric or femoral shaft) femur fractures.Therefore. . however. bone turnover markers increase. Raloxifene. or a fracture occurs. Patients at high risk may be continued on bisphosphonates after 5 years. if osteoporosis is mild.[82] Overall.[73] BMD and bone turnover markers should be monitored during the drug holiday. decreases bone resorption through actions on estrogen receptors.

initial studies using a combination of concurrent PTH and bisphosphonate therapy showed decreased benefit compared with therapy with either agent . Teriparatide is given for a maximum of 2 years. otherwise the BMD slowly deteriorates to pretreatment levels. bone density stabilization while on extremely low-level bisphosphonate therapy. 86.[84] Teriparatide Teriparatide (human recombinant PTH 1-34) is the only available anabolic agent for the treatment of osteoporosis. Teriparatide should be considered in younger and older postmenopausal women with severe osteoporosis. Most studies with PTH have been performed on women. or a very low initial bone turnover rate for which an anabolic effect is clearly warranted. a fracture occurring while on bisphosphonate therapy. all-cause mortality was 10% lower among older postmenopausal women receiving raloxifene. leading to a net loss of bone. after which time the gains in BMD achieved with PTH are secure and can even be augmented with bisphosphonate therapy. It has been shown to increase the incidence of deep vein thrombosis and hot flashes. it is associated with increased osteoclastic and osteoblastic turnover. Pooled mortality data from large clinical trials of raloxifene (60 mg/d) were analyzed by Grady et al in 2010.[88] According to Finkelstein et al in 2003. When compared with placebo. 87] Indications for PTH in men and women are a bone density decline while on bisphosphonate therapy. serum concentrations of total low-density lipoprotein cholesterol were lowered. However. BMD was increased.Raloxifene may be most useful in younger postmenopausal women without severe osteoporosis. noncancer deaths. The medication decreases the risk of vertebral and nonvertebral fractures to the same extent as bisphosphonates. PTH has been demonstrated to lead to a very active anabolic phase. In 601 postmenopausal women who had daily therapy with raloxifene. When PTH is given continuously. with bone mass increasing up to 13% over 2 years in the spine and to a lesser degree within the hip. The primary reduction was in noncardiovascular.[85. in an intermittent subcutaneous administration of 20 mcg/d. and the endometrium was not stimulated.

but this route is rarely used.alone.[90] This pulsed regimen appears to take advantage of the 3. Calcitonin Calcitonin is a hormone that decreases osteoclast activity.[89] A 2005 study by Cosman and colleagues challenged this conclusion by giving 3-month-on. 1226 untreated postmenopausal women had 1 or more vertebral fractures at baseline. respectively. 92] Data on the use of PTH in men are much more limited. in which the markers of bone formation rise more quickly than the markers of bone resorption. 3month-off pulses of teriparatide while the subjects were on weekly alendronate.[93] In this study. the general recommendation is that these drugs be given separately and in sequence. BMD in the spine increased above that of the alendronate-only arm. respectively. and 70%. Studies by Deal et al and Ste-Marie et al on women have shown that the concurrent use of estrogen or raloxifene can enhance the bone-forming effects of teriparatide. Teriparatide reduced the risk of any new. 196 (16%) had a total of 292 new vertebral fractures. During the 2-year follow-up. It is delivered as a single daily intranasal spray that provides 200 U of the drug. 54%. but they appear to have relatively comparable efficacy. thereby impeding postmenopausal bone loss. and 53%. The drug can be delivered subcutaneously. and new nonadjacent vertebral fractures by 72%. whereas raloxifene reduced the risk by 54%. 47% of fractures were adjacent to a previously existing fracture. compared with placebo. compared with placebo. Bouxsein et al retrospectively analyzed data from the Fracture Prevention Trial and the Multiple Outcomes of Raloxifene Evaluation trial for the risk of new vertebral fractures adjacent to existing vertebral fractures in postmenopausal osteoporotic women in patients on teriparatide or raloxifene and found that teriparatide reduced fracture risk to a greater extent than raloxifene.to 4-month so-called anabolic window.[91. . 75%. new adjacent. therefore.

95] It is indicated for patients with postmenopausal osteoporosis at high risk for fracture. In a randomized placebo-controlled trial of 7868 women aged 60-90 years with osteoporosis who received either denosumab 60 mg SC or placebo every 6 months for 36 months. In the first 2 years. a single subcutaneous dose of denosumab decreases bone turnover markers within 1 day. and radial BMD.[94. denosumab significantly increased lumbar spine. femoral neck. Denosumab was shown to increase BMD and decrease bone resorption in postmenopausal women with osteoporosis over a 12-month period. Denosumab was approved by the US Food and Drug Administration (FDA) in June 2010. .[92] It decreases bone resorption by inhibiting osteoclast activity. and hip fractures in women with osteoporosis. calcitonin has been found to increase spinal BMD by approximately 2%. Calcitonin also has an analgesic property that makes it ideally suited for the treatment of acute vertebral fractures.Results from a single controlled clinical trial indicate that calcitonin may decrease osteoporotic vertebral fractures by approximately 30%.[97] In this study. hip. It has been studied in cancer patients and in patients with postmenopausal osteoporosis. Cummings et al found that denosumab decreased the risk of vertebral. Calcitonin is an option for patients who are not candidates for other available osteoporosis treatments. In patients with multiple myeloma or bone metastases from breast cancer. and this effect is sustained through 84 days at the higher doses used in one study.[96] Smith et al reported a reduction in incident vertebral fractures when denosumab was used in 734 men receiving androgen-deprivation therapy for prostate cancer compared with placebo. nonvertebral. Denosumab Denosumab is a humanized monoclonal antibody directed against receptor activator of nuclear factor-kappa B ligand (RANKL). which is a key mediator of the resorptive phase of bone remodeling.

Jamal et al conducted a randomized placebo-controlled trial of women who applied daily nitroglycerin ointment for 24 months. . Strontium ranelate Evidence indicates that strontium ranelate (available in Europe) reduces the risk of fracture. although headaches were a limiting factor for many patients. risks for breast cancer. Data from the Women's Health Initiative confirmed that HRT can reduce fractures. and venous thromboembolic events) and estrogen alone (eg.[99. Other medical treatments Based on preliminary data that suggest women on nitrates have higher BMDs and lower fracture risk. the results of the Women's Health Initiative were distressing with respect to the adverse outcomes associated with combined estrogen and progesterone therapy (eg. 100] Strontium is not approved for the treatment of osteoporosis in the United States. Surgical Care The goals of surgical treatment of osteoporotic fractures include rapid mobilization and return to normal function and activities.Because the overactivity of RANKL is a major factor in bone loss in patients with autoimmune and inflammatory disorders.[98] However. denosumab may become first-line therapy for these patients. it is important to mention because many osteoporosis patients in a typical practice still use it for controlling postmenopausal symptoms. stroke.[101] The nitroglycerin ointment increased BMD and decreased bone resorption. Other nitrate preparations may be better tolerated and could show efficacy for fracture risk reduction. myocardial infarction. risks for stroke and venous thromboembolic events). Although HRT is not currently recommended for the treatment of osteoporosis. Hormone replacement therapy Hormone replacement therapy (HRT) was once considered a first-line therapy for the prevention and treatment of osteoporosis in women. Traditional operative management of vertebral compression fractures is uncommon and is usually reserved for gross spinal deformity or for threatened or existing neurologic impairment. such as ulcerative colitis.

This procedure can be performed on an outpatient basis under local or general anesthesia with fluoroscopic assistance. Vertebroplasty and balloon kyphoplasty are indicated in patients with incapacitating and persistent severe focal back pain related to vertebral collapse. 1-4 mL of a specially prepared PMMA-containing enhanced radiographic visualization material is then inserted directly with a syringe. PVP with PMMA was then used for other lesions that weakened the vertebral body. The first indication for this treatment was aggressive vertebral angiomas. The failure rate of spinal arthrodesis is significant because achieving adequate fixation of hardware in osteoporotic bone is difficult. Bone grafting is routinely performed to achieve bony union. Because this is a continuous insertion into an unprepared bed. The procedure involves percutaneous injection of PMMA into a fractured vertebral body. PMMA is the principal component of bone cements used for rapid stable fixation of implants. . cages. such as metal and plastic prosthetics placed in living bone during orthopedic procedures. such as malignant tumors.Operative interventions include anterior and posterior decompression and stabilization with placement of such internal fixation devices as screws. or rods. a venographic injection is often used to ensure that the needle is not directly aligned with an exiting vein. vertebroplasty is used for lesions above T8 and kyphoplasty is used for the remainder. Vertebroplasty Percutaneous vertebroplasty (PVP) with polymethylmethacrylate (PMMA) was developed in 1984. transpedicular approach. Moreover. plates. PMMA is used in PVP to fortify a collapsed vertebral body and stabilize the vertebral column. After verification of appropriate placement. At the primary author's institution. patients who are elderly have a reduced osteogenic potential. One or more levels of the spine can be treated in a single setting. PVP is one therapeutic alternative for the treatment of pain associated with compression fractures. Percutaneous vertebroplasty. either through a transpedicular or an extrapedicular route (see the image below).

The balloon is then removed. The patients were tracked for an average of 9 months. Jensen et al studied age-related or steroid-induced osteoporotic vertebrae with partial compression fractures in patients who underwent PVP with PMMA. All the patients who experienced pain relief noted increased mobility and decreased need for narcotics.[102] A total of 48 vertebrae in 30 patients were injected. initial studies report good results.[103] However. An extrapedicular approach is used in the midthoracic region. PMMA is infiltrated into the cavity. the procedure does not have the potential to correct compression deformities. but a few key differences exist.[104] Kyphoplasty involves the insertion of an inflatable balloon tamp into the vertebral body under fluoroscopic guidance. and the rate of long-term pain relief was reported to be approximately 80%. Kyphoplasty The second therapeutic alternative for vertebral compression fractures is balloon kyphoplasty. although the bone cement is injected under pressure. Kyphoplasty is similar to vertebroplasty. The balloon is instilled with radiographic contrast material at pressures up to 360 pounds per square inch. the risk of cement extravasation is reduced (see the images below). Whether this pain relief was related to mechanical stabilization of the spine or was secondary to neurotoxic effects of PMMA remains to be determined. success with vertebroplasty may be limited by the lack of significant height restoration and the high rate of cement extravasation. In addition. thereby creating a cavity. In general. which compacts the cancellous bone and re-expands the vertebral body. which has been used since the mid 1990s. while a pedicular route may be used in the thoracolumbar or lumbar spine.One drawback of PVP with PMMA is that. extravasation of the cement into the epidural space is a potential complication of this method. and 90% of the patients described marked improvement of pain within 1 week of treatment. stabilizing the vertebral body and restoring vertebral body height. thus reducing the fracture. . Because the cement is injected into the cavity under lower pressure than is used in PVP.

with resulting improvements in independence and quality of life. vegetables such as turnip greens. and fortified food such as orange juice. A diet that includes adequate vitamin D and calcium is essential. men older than 50 years. Lateral radiograph of the patient seen in previous image following kyphoplasty performed at 3 additional levels. (B) elevating the depressed endplate. the cavity (C) is filled under low pressure with a viscous preparation of methylmethacrylate (D). and other persons at risk for osteoporosis should receive a total of 1200-1500 mg of calcium daily. This procedure has been successful both in reducing the amount of kyphosis and in restoring vertebral body height. Reduction in kyphotic angulation after kyphoplasty. Postmenopausal women. and compacting the remaining trabeculae to the periphery. Kyphoplasty has been performed at one level. Recommendations for patients with osteoporosis include daily dosages of 400-800 IU of vitamin D and 1200-1500 mg of calcium. nuts. It also has successfully reduced pain. See the National Osteoporosis Foundation Web site for further calcium recommendations. Osteoporosis. It is then inflated. Studies have shown kyphoplasty to be a safe and minimally invasive spine procedure that results in improved function in elderly patients. allowing them to participate in increased activities. particularly in childhood as the bones are maturing. sunflower seeds. tofu. sardines. Premenopausal women and men younger than 50 years without risk factors for osteoporosis should receive a total of 1000 mg of calcium daily. . Lateral radiograph demonstrates multiple osteoporotic vertebral compression fractures. Once the balloon tamp is deflated and withdrawn. creating a central cavity.In kyphoplasty. Good sources of calcium include dairy products. Dietary Measures Adequate calcium and vitamin D intake are important in persons of any age. Patients who ingest inadequate amounts of vitamin D and calcium should receive oral supplementation. Osteoporosis. a KyphX inflatable bone tamp is percutaneously advanced into the collapsed vertebral body (A).

A comfortable mechanical support for the spine and. A meta-analysis of 12 double-blind. and respiratory depression. and fortified food such as milk and orange juice. liver. which can occur with the use of narcotic analgesics. alcohol can result in hormonal deficiencies and can increase the tendency for falls Anorexia nervosa . in some cases. butter. The primary reason for the application of a thoracic orthosis is to limit motion in the spine. The length of time a patient should wear a rigid spinal orthosis is undetermined. See the National Osteoporosis Foundation Web site for further vitamin D recommendations. Oral analgesics on a regular schedule can be implemented. an eating disorder.[105] have been strongly associated with bone loss. All adults older than 50 years should receive 800-1000 IU of vitamin D3 daily. may need to be prescribed.Poor nutritional states.Excessive alcohol intake can interfere with calcium balance by increasing PTH production and by inhibiting the enzymes that convert inactive vitamin D to its active form. is essential.and longterm morbidity. a thoracic orthosis.Adults younger than 50 years should receive 400-800 IU of vitamin D3 daily. Spinal compression fractures can be extremely painful and can cause short. fatty fish. in addition. Good sources of vitamin D include eggs. which result from low body weight. urinary retention. Pain-relieving modalities such as moist hot packs and transcutaneous electrical nerve stimulation should also be considered. monitoring the patient carefully for signs of constipation. low estrogen states. result in significant bone loss) Physical Therapy and Exercise The first goal of rehabilitation in osteoporosis patients is to control pain if a fracture has occurred. controlled trials (RCTs) for nonvertebral fractures and 8 RCTs for hip fractures that compared oral vitamin D (with or without calcium) with either calcium alone or placebo found that nonvertebral fracture prevention with vitamin D was dose dependent and that a higher dose reduced fractures by at least 20% for individuals aged 65 years or older.[75] The following conditions can interfere with nutrition: Alcohol intake . During this period. such as in anorexia nervosa. nutritional and endocrine factors contribute to bone loss (in particular. . randomized.

thereby reducing the risk of falls. flexibility. Physical therapy then focuses on improving a patient's strength. Sinaki and Mikkelsen showed that exercises that place flexion forces on the vertebrae tend to cause an increase in the number of vertebral fractures in patients.[109. trochanter. therefore.What is well known is that immobilization contributes to bone demineralization. Regular weight-bearing exercises are essential for the maintenance of bone mass[24] and should be encouraged in all patients. deep breathing exercises. and peak exercise oxygen consumption (VO2 max).[112] . ensure the patient maintains an upright spinal alignment. During the early mobilization period.[111] Also.[108] Sinaki and others found that strengthening the back extensor muscles reduced kyphosis and decreased the risk of sustaining vertebral compression fractures. such as walking and bicycling. Aerobic low-impact exercises.[108] In postmenopausal women. Snow et al found increased BMD of the femoral neck. Spinal BMD is directly correlated with the strength of the back extensors. muscular endurance. maintaining and strengthening the back extensors should be emphasized. and total hip in 18 postmenopausal women (average age 64 y). and back conservation techniques need to be implemented. as well as improved quadriceps strength. generally are recommended. In 1984. weightbearing exercises should be initiated. while values in the control group declined. During these activities. pectoral and intercostal strengthening. Women who exercised had increased bone mineral density in L2-L4 and the femoral neck. 107] Postural retraining is key in this population. and balance in order to prevent falls and maximize his/her physical function. Exercise also improves agility and balance.[106. impact exercises can increase BMD in the hip and spine. 110] As soon as the course of therapy allows. including children and adolescents (in order to strengthen the skeleton during the maturation process). Chien et al examined the efficacy of a 24-week aerobic exercise program consisting of treadmill walking followed by stepping exercises in osteopenic postmenopausal women aged 48-65 years. who wore weighted vests and participated in jumping exercises 3 times per week for 32 weeks of the year over 5 years. posture.

87 versus 1. respectively). Balance training incorporates the strengthening of various parts of the body (eg. Wolf et al monitored 200 elderly community dwellers who received Tai Chi and computerized balance training. aiding in the prevention of a kyphosis. Tai Chi was shown to reduce the risk of multiple falls by 47. The authors found that after one year.34. the authors documented decreased fear of falling responses.[113. The physical therapist must address balance training.[117] Campbell et al monitored 233 elderly community dwellers randomized to an individually tailored physical therapy program in the home compared with usual care and an equal number of social visits. Isometric exercises should also be used to strengthen abdominal muscles. subjects in the exercise group had improved balance. and knee extension strength. 114. Carter et al demonstrated that osteoporotic women aged 65-75 years who underwent a 10-week community-based physical activity intervention program improved their static balance. spinal extension. Improving one's balance can significantly lower the risk of falling. In addition. proprioception. In addition. 115. dynamic balance. although they did not benefit from a significant reduction in fall risk factors. and low-impact cardiopulmonary fitness. because fall prevention is important in eliminating the complication of fracture. After a 15-week intervention.Although swimming is not a weightbearing exercise that will improve BMD. with each session lasting 45-60 minutes. Other types of exercise training programs may also positively impact balance and strength. Several different exercises have been shown to be beneficial in patients with osteoporosis. 116] Tai Chi Chuan and specific physical therapy programs have been shown to be particularly effective in improving balance and reducing falls. it does provide chest expansion. trunk. and vestibular input. the mean rate of falls was lower in the exercise group than the control group (0. legs).5%.[118] Occupational Therapy . The patient should be instructed in a home exercise program that incorporates the necessary elements for improving his/her posture and overall physical fitness. Proper therapy for osteoporosis includes 3-5 sessions per week of weight-bearing exercises. after 6 months. such as walking or jogging.

sodium. 1. behavior modification and pharmacologic interventions. stairs.7% ± 0. Recommendations included the .2% at the lumbar spine. as well as the removal of throw rugs.1% at the hip. and adaptive bathing devices also can be beneficial. pharmacologic treatment. Prevention of Osteoporosis Primary prevention of osteoporosis starts in childhood. caffeine.[123] They found that the women who received placebo lost BMD at all measured sites. animal protein. Patients require adequate calcium intake. the recommended dosage is the equivalent of 5 mg/d. In 2010.[121] Pharmacologic prevention methods include calcium supplementation and administration of raloxifene or bisphosphonates (alendronate or risedronate). doses of 2. 120] Patients should be counseled on smoking cessation and moderated alcohol intake.5% ± 0. The use of a shower chair. tub bench. In a study by Hosking et al. Raloxifene and bisphosphonates should be considered as first-line agents for the prevention of osteoporosis. Beyond this.5 mg and 5 mg of alendronate were evaluated in postmenopausal women who did not have osteoporosis.[122] When alendronate or risedronate is used for prevention. and 0. the American College of Rheumatology published revised recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. and weight-bearing exercise. The National Osteoporosis Foundation (NOF) specified that the following behaviors should be modified to reduce the risk of developing osteoporosis: cigarette smoking. physical inactivity. prevention of osteoporosis has 2 components.9% ± 0. The application of nonskid tape to steps (indoors and outdoors). and calcium.[119. in some cases. and intake of alcohol. and bathrooms.Training in the performance of activities of daily living (ADLs) and in the proper use of adaptive equipment are essential to the prevention of future falls. greatly improves home safety. Patients who have disorders or who take medications that can cause or accelerate bone loss should receive calcium and vitamin D supplementation and.1% for the total body.[107] Home modification focuses on reducing the risk of falling by installing handrails and grab bars in hallways. whereas the women treated with 5 mg/d of alendronate had a mean increase in BMD of 3. vitamin D intake.

[125. function-limiting symptomatology that has not been relieved by noninterventional techniques. According to the NOF. Periodic bone densitometry helps in diagnosing osteoporosis in the early phase and aids in preventing fractures. risedronate. Regular weight-bearing exercises and back extensor strengthening help to delay bone loss. 126] Consult an orthopedist to assist with fracture management. Long-Term Monitoring . and teriparatide (in those patients at highest risk). Regular monitoring may be helpful. an invasive pain specialist may be consulted for proper interventional procedures. because it is associated with an increased risk for breast cancer. and perhaps coronary disease. Consultation with a nonsurgical spine specialist is appropriate for a patient who is not a surgical candidate or whose symptoms persist despite surgical fixation. Consultations can include discussions of nonmedical/nonpharmacologic management of osteoporosis. the most important consultation is with a rheumatologist or an endocrinologist. These specialists are helpful in the diagnosis of osteoporosis. zoledronic acid. A rheumatologist may also provide useful assistance with management and determination of underlying etiologies in complex cases. venous thromboembolism. In patients with uncontrolled pain that does not respond to conventional therapies. evaluating BMD on a periodic basis is the best way to monitor bone density and future fracture risk. they can aid in the obtainment of the proper laboratory tests and imaging studies needed to rule out causes of secondary osteoporosis.[63] Bone density checks are recommended every 2 years in postmenopausal women. Consultation with a spine surgeon is appropriate for patients with intractable. Estrogen is now only recommended if patients are also seeking relief of postmenopausal symptoms.[124] Estrogen-progestin therapy is no longer considered a first-line approach for the treatment of osteoporosis in postmenopausal women. stroke. severe.categorization of patients by fracture risk (using the FRAX score) and initiation of treatment in appropriate patients including alendronate. Consultations For a patient with osteoporosis in the diagnostic and therapeutic phases.

and one anabolic agent. with the remainder being rapidly excreted through the kidney. are currently available for osteoporosis treatment. these agents can inhibit osteoclastic resorption. The American College of Physicians has reviewed the evidence and proposed guidelines for pharmacologic treatments of osteoporosis. DEXA should be performed every 1-2 years in patients who are undergoing osteoporosis treatment. state that evidence is lacking about optimal intervals for repeated screening. All therapies should be given with calcium and vitamin D supplementation. and by binding at sites of active bone resorption. including bisphosphonates. (See Treatment. the selective estrogen-receptor modulator (SERM) raloxifene.Dual-energy x-ray absorptiometry (DEXA) should be repeated every 2-3 years if the baseline test results are normal. calcitonin. Bone uptake is 20-80%. All oral bisphosphonates have a poor absorption and a bioavailability of less than 5%. however.[64] Orthotics are used to decrease the flexion forces to prevent the worsening of kyphosis and to reduce the pressure on the fracture site in the acute phase of disease. teriparatide. Bisphosphonates have a high affinity for hydroxyapatite crystals. The USPSTF 2011 recommendations.[127.) Bisphosphonate Derivative Class Summary Bisphosphonates are stable analogues of inorganic pyrophosphate.[129] . denosumab. 128] Common orthotics used include the following: Thoracolumbosacral orthosis (TLSO) Cruciform anterior spinal hyperextension (CASH) brace Jewett brace Medication Summary Antiresorptive agents.

It is approved for treatment and prevention of postmenopausal osteoporosis. View full drug information Zoledronic acid (Reclast) . It reduces vertebral fractures by 50% with intermittent (nondaily) dosing over 3 y. It reduces the incidence of vertebral fractures by 47% and nonvertebral fractures by 50% over 3 y. It reduces vertebral fractures by 41% and nonvertebral fractures by 39% over 3 y.5% and the hip by 2. male osteoporosis.8%.4% and the hip by 1. Ibandronate is approved for postmenopausal osteoporosis. and steroid-induced osteoporosis. View full drug information Ibandronate sodium (Boniva) Ibandronate increases BMD at the spine by 5. osteoporosis in males.6%.5%. male osteoporosis. Alendronate is also available in an oral (PO) solution taken weekly. and steroid-induced osteoporosis. alendronate sodium/cholecalciferol (Fosamax Plus D) Alendronate increases bone mineral density (BMD) at the spine by 8% and the hip by 3. View full drug information Alendronate sodium (Fosamax). it has no effects on reduction of nonvertebral fractures. and steroid-induced osteoporosis. risedronate sodium with calcium carbonate (Actonel with calcium) Risedronate increases BMD at the spine by 5. A tab is available with 2800 or 5600 IU of vitamin D3.Bisphosphonates are approved in the United States for the prevention and treatment of postmenopausal osteoporosis. View full drug information Risedronate sodium (Actonel).4-2. Alendronate is approved for treatment and prevention of postmenopausal osteoporosis.7-6.

When given intermittently. It reduces the risk of spine fractures by 65% and nonspinal fractures by 54% in patients after an average of 18 mo of therapy. PTH increases bone remodeling with the net effect of increased bone mass and improved skeletal microarchitecture.Zoledronic acid is the most potent bisphosphonate available.[19] View full drug information . and intestinal calcium absorption. thus regulating calcium and phosphate metabolism in bone and kidneys. leading to increased BMD. renal tubular reabsorption of calcium and phosphate. This anabolic agent acts as endogenous PTH.1-3. Zoledronic acid is approved for the treatment of postmenopausal osteoporosis. It reduces the incidence of spine fractures by 70%. respectively. It increases BMD at the spine by 4. which increases bone resorption with a net effect of decreased trabecular bone volume). hip fractures by 41%. It works primarily to stimulate new bone by increasing number and activity of osteoblasts (bone-forming cells). and nonvertebral fractures by 25% over 3 y. View full drug information Teriparatide (Forteo) Teriparatide is recombinant human PTH 1-34. Teriparatide is approved for men or women at high risk of fracture due to primary or hypogonadal osteoporosis or postmenopausal osteoporosis. PTH promotes new bone formation. Additional physiological actions include regulation of bone metabolism.5% compared with placebo. which has identical sequence to the 34 N-terminal amino acids (the biologically active region) of 84-amino acid human PTH. Endocrine and Metabolic Agents Class Summary Peptide hormones that modulate osteoclast and/or osteoblast function have been shown to be effective in the treatment of osteoporosis.3-5.1% and the hip by 3. (This is in contrast to continuous exposure to PTH. Teriparatide increases BMD at the lumbar spine by 9-13% and the hip by 3-6% compared with placebo.

Raloxifene is approved for the prevention and treatment of postmenopausal osteoporosis. View full drug information Raloxifene (Evista) Raloxifene increases BMD at the spine and the hip. Diminution of benefit may occur after 20 months with the parenteral form.5%. Biologic and Immunological Agents Class Summary . studies do show an increase in BMD with the use of calcitonin. however. It reduces the incidence of spine fracture by 33% in group receiving 200 IU/d. Calcitonin increases BMD at the lumbar spine by 1-1. the intranasal form is more convenient and better tolerated. It is most suitable in women < 70 y at moderate risk for osteoporosis who have infrequent vasomotor symptoms of menopause (eg.Calcitonin (Miacalcin. Fortical) Calcitonin is a peptide hormone used to treat and prevent osteoporosis in patients in whom bisphosphonates and estrogen are contraindicated or not tolerated. hot flashes) and who are at moderate-to-high risk for breast cancer. However. It inhibits osteoclastic bone resorption. It reduces the incidence of spine fractures by 30-55% over 3 y. Like estrogen. these are antiresorptive agents. because of their selective receptormodulating property. they provide the beneficial effects of estrogens without the adverse effects. depending on the organ system. It is available in parenteral and intranasal forms. Although no research data support the idea that the use of intranasal calcitonin reduces the incidence of fractures. It also has some analgesic effects in patients with fractures. Selective Estrogen Receptor Modulator Class Summary Selective estrogen receptor modulators (SERMs) affect some of the receptors stimulated by estrogen but can selectively act as antagonist or agonist.

[72] Calcium citrate and vitamin D (Citracal-D) Calcium supplementation in patients at young ages has been proven to lower the incidence of fractures.Monoclonal antibodies that prevent the formation of osteoclasts. View full drug information Calcium carbonate (Oystercal. leads to a decrease in bone formation and increase bone mass. Vitamin D repletion is essential for calcium absorption. and survival of osteoclasts. . failed other treatments). Calcium supplements are used to increase calcium levels. View full drug information Denosumab (Prolia) This agent is a monoclonal antibody that binds to the receptor activator of nuclear factor-kappa B ligand (RANKL). which. Caltrate) Calcium carbonate is commonly found on the market. have been shown to be effective in the treatment of osteoporosis. function. especially in patients taking antacids or proton pump inhibitors. the cells responsible for bone resorption. history of osteoporotic fracture. Vitamins and Calcium Salts Class Summary Calcium and vitamin D are essential in order to increase bone density. in turn. Calcium citrate is better absorbed than calcium carbonate. a transmembrane or soluble protein essential for the formation. It is indicated for the prevention of fracture in postmenopausal women with osteoporosis and high fracture risk (ie.

occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. of preventing or delaying cardiovascular disease. and many proteins in target tissues. presumptively. decreases the rate of bone resorption. it was instead found to increase the risk of breast . 17-alpha-dihydroequilenin. RNA. They are used to increase serum estrogen levels. Multiple aspects of menopause respond to estrogen replacement therapy. 17-alpha-estradiol. Estrogen had the additional advantages of controlling menopausal symptoms and. as concomitant components.Estrogen Derivatives Class Summary Estrogen derivatives are approved for the prevention of osteoporosis and relief of menopauseassociated vasomotor symptoms and vulvovaginal atrophy. They increase synthesis of DNA. sodium sulfate conjugates. Such therapy also reduces bone resorption and may increase osteoblast activity. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. However. estrogen replacement was considered a primary therapy for the prevention of postmenopausal osteoporosis. It contains. including vasomotor symptoms and atrophic vaginitis. and 17-beta-dihydroequilenin. in turn. which. In the past. View full drug information Conjugated estrogens (Premarin) This agent contains a mixture of estrogens obtained exclusively from natural sources. The FDA recommends that other approved nonestrogen treatments should be considered first for osteoporosis prevention.[130] The lowest effective dose at the shortest duration necessary should be used. Conjugated estrogens restore estrogen levels to concentrations that induce negative feedback at gonadotrophic regulatory centers. which in turn reduces release of gonadotropins from pituitary. data from the Women's Health Initiative (WHI) revealed that estrogen-progestin therapy does not reduce the risk of coronary heart disease.

low dose of Premarin. with frequent monitoring. View full drug information Ethinyl estradiol and norethindrone (Femhrt) Ethinyl estradiol with norethindrone is used to treat moderate-to-severe vasomotor symptoms and to prevent osteoporosis associated with menopause. routinely prescribing conjugated estrogens to premenopausal women is not recommended. .cancer. Climara. For postmenopausal women with an intact uterus. As such. Other antiresorptive agents are now the drugs of choice and are prescribed more frequently for the prevention and treatment of osteoporosis in postmenopausal women. reduces the release of gonadotropins from the pituitary. evidence suggests a reduced incidence of fractures. Estraderm. This medication should be used in postmenopausal women who are incontinent and who have had a hysterectomy. this. Premphase) The combination of conjugated estrogens and medroxyprogesterone reduces bone resorption and retards or halts postmenopausal bone loss. cautiously recommend a short-term. Vivelle. and many proteins in target tissues. View full drug information Conjugated estrogens/medroxyprogesterone acetate (Prempro. In addition. it also inhibits osteoclastic activity and delays bone loss. RNA. in turn. Alora) Estradiol restores estrogen levels to concentrations that induce negative feedback at gonadotropic regulatory centers. View full drug information Estradiol (Estrace. Estradiol increases the synthesis of DNA. and venous thromboembolic events. stroke.

78  2./ 094 0.

/ 0940.78  2.

5#%(   2./ 00.02039907..78.3/4/07 43420334943472430705.

/ 00.3/4/07  2.78.

/ !703..3947.934203   2.9.

81448 0940.:239. 89045474884:3/./  :7703970.9438174290.943.42203/..0 .943147/.78  2..70..

78  2./ 0940.

/ .

78  2.0940.

78  2./ 0940.

/ 0 0.3/4/07  2.78.

3/4:307  2.3/-70.89100/34203./ !703.39.00.78.

/ !703.  2.89100/34203.

8.1074 .23705090 /0130/.9.40.23  47.90398706:702470 .438/070/.07.83-0370.0 1:3./  '9.35.000203934.. / 94-0 .2383.903989489045474888 &41.943 %0232:2/.

943.209..9:708.8841/4:-0 -3/ 7.0790-7.3/ 5488-.9:70570.9:708-.23 . (  209.43083490110..90/95.88415.:2 517.9343...425.90/9/09.9:708 07070/:.3.9.94341.23.884.9439..439740/97.90/943 9072.:..:/0/.03.3/420/.80/43.94: 03.884.:/0/9.7.0/ (%0..43.23 8/480 /0503/039 .43.:28:55020398 (%8 3.0  .9:708.90.07...439740/97.: 94794:9.. ../:.7347.88.430475.8.3..3.9.9..17.:8438070-.03943...7089:/08 9.723..841343.3/.:28:5502039..3/..89 33/.89  4.0/0243897.017.841517.0/17.7...370/:...3/.34:9.7089:/08.0/ 0.//943.7/4.209...9:708 .3/ 3.90/9.0790-7.3/ .80/78147 24.884.3.9438300/0/70..03570.7/.9439.23.3/09.9:708 .42-3.9:708.17.7788 33./2389070/.07/48070/:.23./2389070/9.:239.903989.9.9.9..:28:55020398 94:9 .. ..3.894303907.420..3/420/ .9:708.3/949.398   47031472.78474/07 (  3.8..8..8349-003.2   $0.3/ 7..17. .884.90707.903989...98:5502039..884117.80/78.:2.90..3/420/9...039439.70..90/.8.0790-7.9.:2  90907.0393 17...7/3788.90.

.3/ 397.439740/..90/.8-003843943.70.9 970.3/570..9908530 5 .039814748904547488 %0.8:83.908 2.908  8548543.03/743.80853.903989 48904547488 %0970.8548543.9203970/:.3/52307.92039.42243:80/.3...:8../03893548920345.9:70.97..908.0-003 02540/147-49970.904117.43/:.08907. 4203 0 .0394341 8904547488  7.-0   03/743.90.70902489.92039/48041.3/789- 35.03/743.70.9084/:23/...909..034:8 ' 459438.03943  $00!70.

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

1742./03.9.420394:980.8-003843943.943841949.039742-488.80903.80/ 807:2 .808 3  548920345.3/491.3.40890740704070/ .#.83.97.3/9003/42097:2 .597.70.//.41030  2.70.8349892:.041/005.9/.43.-02489:801:34:307548920345.:8.42034.07048904547488  9.0397.8417.907.90/   !440/2479.:8.4 /038954574903..70.410302.41030 .

.80/ 48904.7..9.0/-7.3  03.:8..420370.70/95.30948841-430 40.0-4 ..3.920394148904547488 03!%8.9/0  %075.-0./ 070.-4.07/0.98 ( %075.94341 2./ 09..3/48904-.8.3.304:8..4393:4:8 98.07 0..770/:.03.3.7./23897. ..89.943.9/0 :2.8 407.2434/07 548920345.37.33907299039 8:-.83343..89..7/4.7  343.42-3.07 3./394..425..0.41030 %0572..39!%  89043.:9.370.70.03914790 970.:.9:734.884.90/93.:802479.

070.425.94341.08 (  .8-003/0243897.90907.90907.90907.30.70/9907.70..3.-4309:734.70.5 .03 147.89:/08:83.9:70894908.90 907..783908530.-4.590907.83:5944.3  39..5 47.3/ -8548543.4203980...9430430970204 0.0 .3..039 .908 %075..7.3/343.:8.0790-7.390/ %075.0.808907841 .383.7.0-8548543.0110.17.2009039.:70.98.5840//0.:77039!%.920390.5..9/08.08807 /070093905   (  3/.77.883.-4.3.90/940.42-3.9:704.30043-8548543.90907.438/070/34:307.07.5 -430/038989.5 4907809084/090747. 17.80/-03019.8-8548543.70.9438147!%3203.9/084:/-0.47/39430890309.3/4203.:773043-8548543.9.07439.03-0.:20390/9-8548543.7.3/94./ !%.92090..0.-..1907..90147 .90894 570970.943/0..2..0790-7.80 9-4302.07048904547488   48989:/089!%.3/ .43.3/ 4/07548920345.78 .077../94.-430/0389/0..70.0/9!%.2:2410.7080.0-00350714720/434203 %020/.

9.9433  .3/$90 .0-4  .70.03994.9.8.907090399.7.3.:9.090-430 147230110..3.990.80848904..9:708-  .070.08439.03/743.070/.0790-7.70.1742907.41030 (  39889:/ :3970.570.9:708.-4.90.3/4 3.9/070/:.4130.09...3-0/0.43090701470 900307.3 2439 43  2439 4115:808419075.9/0.7.9:708070..43.03805.039 .././472470./.7.3902.:843-.9:708 4117.434203.0 (   89:/-482.7.8.707841-430 1472.98419075.9:70!70.980704300.90/548920345.0790-7.40.4203.0//.17.:8.9/0  (./.9.41030..0/9078-  .78949..09.41030.99075.9/070/:.70974850.17.:77039:8041 0897403477.0 ..41030..0 .90390 85303.3/   70850.030/98.3/14:3/9..3/3 806:03.3/.3 30 30..070/8:-.70/95.70..9/00908:-0.4103070/:.87.03994 0893.3/  70850.7.14790784130.0/17.17.70/95.:08.7.   4:80309..397./.9 -.9:707894.304:8 -:99874:9087.9:7083548920345. -430488 98/0.99080/7:8-0...0790-7.0790-7.7009..9.:.3/90:950 :9..94338.70.9..9.3.902.039.17.0/..0 .0.42203/..90398439075.:8.17.90 43./08 &4190/7: %0 /7:.794.0./.425.8030 :7390 0.94397.550.04190 94 243984 ..707841-430708475943   $9:/08-0.-0 011.:8./.7144 :5   .4890454749....70:80/   .72  (%85:80/70203.9 9070-250/3548920345.-4..03/743.9/047 7..420841#.702:.39.94389.9574.830/.4724309.3.3.9:70 %075.0-4 070.43.420335.2470290/ -:990.9.9:708.9.857.94190.94378024706:.9.949.425.0790-7.7.3/30343.89..4390 :8041!%3203.303..550.03943%7.3 7...0/907841.80/.4:8089317..425.

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

0/3.08 4774/8 4307.8730  304724700.7974/0888831.0/7.4.90/94.94341!394..34:95.907.9039893.425708843.89 !'! 954209209.39073.97.0841908530.92039.5.884.3/54890747/0.07  5..390747.0790-7.:80988...3/89.9432.:9..0790-7..:/0.398 8:..304:8.89  !07.3/-.8889..580/.700/07.908 .70/:.1.5748909.557457./06:.0790-745.7.4393:4:83807943394.0394383..342.03 1907...:..-4308/11.3/07  '0790-745.0  !07.3:35705.85.:947 83899:943  ..304:8.3303.0/4890403.:9 4704.3/5.   '0790-745.8209..470307.:...-01.7.9073.90/9.42570884317.5...708 5.08.580 990572.0790-7.0.03907.17.8/0...88.0..0790-745.90.3850/.8 903:80/1474907084389.02039418:.905..50/.-4/ 0907 974:.02039  241.-.4..898:80/14790702.:9.83080993  .990300/08349/70..3.7034890454749.89 507.071.3.3-430/:73479450/...-4..89.5.-090 .39 -0.91:4748.89.07014.903984.5574.8:.0-43:343 %01..030/90.0%.901.439.93.9041853.08507.   0.8 !'!9!.92039415.:9..014790970.3.45.1938 74:93050714720/94..943841903 :80/94038:709.-.898:80/14708438.0450/3  !890573.70/! .399:2478 !'!8 430907.443545.94341 25.020398:80/1477.5705.:707.4..89.9:70/.9.774:90 800902.549039. 574..703/.850..3/545.0-04 %8574.0347.0790-745..9:708   %0574.0790-7.308908.5/89.9.-4/.30.94341 .0790-7.3850/.304:830. .3-0 50714720/43.4:23   %017893/.90/ 5.70/-0/ .3.747.0/:708 !8:80/3!'!9414791.7.94341.90 ! .0.:.:80.3.-4/ 8:.50:9..88:3/074.3/ 50788903980./47..3 -0970..7/.0/:70..0790-7.99.8903380790//70..3093.5.

08089  (  545.3894-0/0907230/   30307..703.892.0790-7.-4/:3/07 1:4748..0/ 9070-.5.9:7088-.89:/0870547944/708:98  (40.02039830.08.89  ..90398/08...9041.39017.89  %080.9 !83197.02039097.-...02039097.04124398 .70/2574.0790-7.42570884317.89:/0/..943. 39.0 70.50:9.08-04  .. 50/..44383890/9 7.3909708947.0 3097.90/9420.41.94341982094/   0380309..9039807030.9039807097.-390.89 -:9.4770.549039.-4/..880.331.443545.3.50/.9890 .49..9841! 702.095.4.70..0889.0790-7..41!'!9!89..07.4439.3 930041970.3//0.55742.794.8-003:80/83.9.0/:70/408349.90/:3/0757088:70  90574.0902/ 8 545.89.90/ ...:/.425708843/01472908 3.893.8.907.747:2-.0890380794341..0/ 800902.70./47.90/ 39490..93...0790-7.425.8.100 /110703.9:70   %0-.80/300/1473..37001.-0:80/390947.774:902.8 %05.79430:7494.903984:3/07039!'!9!  (949.4:2-.8:80/3902/947.89882..9.02039830.9434190853047.42570884317..0110.7.5574.9438 70/:.78530 %0-..0 3 5.90  0907985.090549039.04:8-430.43/907.0/5.:.7-0/2.9:70835...9 .0790-7.-0 290/-90..//943  097.0147.94:90-430.3/907..9  89..-4/ 9:870/:.7.0790-7.87054790/94-0.38:80/3!'! 907841.3/890.-.9434190.79.020393949005/:7.4397.02039415.41831.2539490.3/90 7.90/39490..80/24-9 ..904143 90725.44389037024..3.:.425.9073.3.9.0790-745..43/.0790-7.45.7043 0..-0-.3/ 41905.07 8:...0/147.9:3/0740757088:709.85.3/7089473.:8090.892.37001. . .-4/09 0.8 70.0790-745.70..3/70 05.90/4789074/ 3/:.903984050703.3. 30/7..943  545.370013490/3.957088:708:594 54:3/850786:..8.94.92039 905..0/4890454749.

0790-7.3  0.7/308 3:98 8:31407800/8  941: ..9430-8901471:7907.9.943   /099.:2.90398 .0..43902945.3/  241 .0.7894:9781.-0-4309.8994 -0.93.//943.9433549..70.258507.:28088039.70.:.3:.90398430893./ 241..0 $0090.5/0243897.3/6:..09490507507  3.8:708  /06:.8.:/  .78 .94381475.9  810/:3/07457088:709.3 $9:/08.7574/:..8-0038:..:270..93..73 .847..7025479.4203..7. 44/84:7.0841  &41.94330/07 5.4203 2034/079.41  241 .23.9781474890454748884:/70.3/.:/0/.943.3/9/7.090-.98 8.0881:70/:./06:.94341 209209.9082:9504890454749..24:39415488.-4/09 9.0/5.3 0.08   %8574. .:/0/.0/:70.90/.:9.0  8904547488 .1907545.3/./..9.4:85705..79..88:.0.3/ .0397.3/.3397...0841.7.3.531.89 ..9390702.2339..0881:-49370/:..393507843841.947814748904547488 84:/70.258 /01.-4/  9890331.9.390.8-00350714720/..:2/.0843545..0...3 90.0/39490.7.80/./48.425708843 17...0/:709./44/./06:./47. #0.9390/0570880/03/5.08530574.908 9708:932574.-0.01443545.94300.24:39841.94110  09.8:5502039.-088:.8.304:8.907.3/2034:3079.0790-7.4439..949..0 5.890-4308.9708:9832574.23.4:82.3/232.:23.903980033570.42203/.907.425.0.42203/..23.90..90 .90.3/49075078438.5.89.0/1:3.10.047..:2/..:8.:8.:284:/70.0.89:73570038 ..0790-7.79...541905.9 .90398 9489045474883.90   #0/:.3/37089473 .7.70.:.:2   !7020345.943. 89045474884:3/.89 50714720/.8.. !48920345.702. 545..949.90/   00.0203983 3/0503/03.3/147910/144/8:.9:73 !.9033.89  8904547488 .30:..580/ .4.

 89045474884:3/.3 24/..8..-9....3.0.48.:770/ $53...8/480/0503/039.23 94794:9.3 0.8841/4:-0 -3/ 7.479488 2..9343.23/.5.70.-020.70.82489495..84-0 ..943..5.808 .3/03/4..2370.8090903/03..0-3.   .307.90398894.08.3470.9.89 1473/..9918 ...3708:9347243.4397-:9094 -430488 35.307.30.42570884317.3 0.0790-7..3 700.770.3/..90/9-4304883:97943.7-0/ %0572.701:14783841.30:.9.9.014723 .:808479 .439745.3.9.3..0 ..9:70570.07 -:9907 1.4794888942924943 3908530 %003941920.89. ..9.9..4170.9.439740/ .90.43.708:917424-4/09 708:93 831.9:708.94341.943../:.17.23 ..908 .07/48070/:.3/47..42203/.70/47../01.3390710709.7884:/70.3/70857.4439.39-430488  !8..7. /:984:3079..3/147910/144/8:.0/:0.421479.0-414:3/9.8:55479147908530.70:.9.9433489045474885.31..3.:/008 .088.23 3..1471..3/ 38420.430475.7301.0  &41..947. 4.9438   209.43/9438.9.7 70903943 .9.82.3-00970205.....3/07.300/ 94-05708../:984/07 9.9.:2.8 3470. 17.7884:/70.38.93/847/07  ( .0892:.039439.//943 .94384:/.83.49.425.7/853.943 :73.:2-.0-00389743.0/17.3.438/070/ :73985074/ 2439473905.9:708.9.7.%07.79.9:708-.0 $0090 .33907107093:97943 .0/ 0.9478..7 4089740389.8 8 088039.0841..908 8:.3/43 9072247-/9  7.:9..884..903984:/0.4439.307.843.9088:.78474/07 (  %01443.80  %017894.:.0.3/..97.9:7089.48.. !4473:97943.33..3/9.17...08.4794888:3/0907230/  ..44.0.3/420/ .:7990:80413.9:70.9430-8901471:7907..0  &41..9039.08.0790-7. 44/84:7..43895.8 #%8 147343.3/97.34. .304:800..0793..84314790.3/#%8147517.3/-3-9390032089.0.:2  90907..947/05708843 .83!% 574/:.947.31:.3-025020390/ !.

98034389.7 24-.590314..43807.943.947.3/2..94390.3/-. .9435074/ /005-70.9039 8897039 10-9 5489:70 .4397-:90894-430/02307.3.:808432574.93007.5.3.489.907..3/3907.9224-.0 347/0794570.8.208...36:08300/94-025020390/   !8..0391.943 :73900.808 50..3/-.897039033 .

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

73007.808 84:/.08 .38..903984:/-03897:./3390570..90/ 3.0 9/408574.-/423.5147489045474883.09-0.08905. .93..94:82238349.9089030.29.7193088 842097.0394341.8.0903843 .73007.84-0:80/9489703903.420007.3/4 25.808 8:.5488   !74507907.805747.2:8.9./0 .007.34743 90.47547.700203981472574.3843 853.7/45:243.808843.:/08 8088438507004109 -0.92574.893  23:908 %05.088.809.

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

03/743.0-4489.20./ 3.8904203970.0.0/5.90070 0.:8.89:/-48309.048904547488 (%014:3/9..90/3548920345.8:70/8908 070..3/241.. /480841 2.9.:.90/9 2.42034//349.990 4203470.

0/48904547488 #0.4.:/0/90 .80/70.4/ 3/:.70.33.9203941:.3/970.20.03943.479.9905 .03/743.-4/   3  90207.78530  ] .42203/./41.94383..3/ ] 14790949.990:2-.90.340041#0:2.80341 ] .9445:-80/70./.42203/.943814790 570.

3/39..80/78147-70.9/0 39480 5.808   438:9.9438.438/070/.903989 :3.03943.94389.3/1:9:7017.5574.90398-17.90 40/743..389:/08300/0/947:04:9.734489 %080850.80./ .:8084180.438:90/1475745073907..808.4743.3488414890454748890.-0051: !074/.70051:390 /..908978 (  897403 5740893907.58344307.42203/0/0....42203/0/15..9:7078 (430/0389 .-47.3.88890-089.:/0/8.70.884.:8.3489.89 .0.898....05.320394190574507.808 90248925479.0/:708   70:2.8259428   #0:.470 ./83570..:/3.94243947-430/0389..33.43.907.7/80.438:9.70.. 5074/.14790970./0:801:.9203941 489045474883548920345.3.724394732.905.3/-.943415.7070.-430488  438:9.9448947.092..58.9438  47.7.3850.3/9075..70:2.:8..070.3//090723.07 89740 .1789 30.-0.:884384134320/.508 .4203 -0.9047.02039.748904547488 35.3.783548920345.944892.3/.-.8.94790898.9:708 ..8.5.4250.039317.:8098.557457.848003700141548920345.439740/5.3/907.03/743.73 007.80 89740383443 70..574.8889.50:9.9039948904547488390/.90398.3.90398..90/9.709 -0.33.89 2.9:7078 :8390#8.94341970...-430/0389420970583/.:8.90 780/743./3904-9.84574.920393 ..33.034:89742-402-482 .3/507.75.303/4.03943.3/ 2.94341 :3/0730944083.4203 #0:.9/408349708543/94..5.903983.39.9343.43/.348348904547488 3900.39 .47/39490  0.09038478970390330594/0..:.

 3438:7.03943..90147..3//.557457.901475.-0 80.9.02039 438:9.8530850.557457.943 9.3479450/8994.44.903948349.8:7.9449.1.85308:70438..8349-003700.0/-3433907..9..9:702.3435.5.8889917..3.070 1:3.9047480 8259428507889/085908:7.943 293 825942.36:08 438:9.72.9439.90.0203941 48904547488  (438:9..2.943  43 %072439473 .903989397.3...898.

1472.990...909.908.5070903843 $ -7.7089.5745485.88$:22.0.970.5.:905.0398 ..38.:77039 .08   990702.08.3/07-037..80  (42243 47949.7.09057088:70439017.8:80/3.9433 /0348:2.:2.-8475943..42203/.9438 40.23 8:5502039.7.3/.3/94 70/:.3 430:59.5447.07 0.70 :3/074348904547488970..8041/80..0894570.89.039 9075..33-948904..78190-...8030 9089708:98.3/--3/3.44.870.9.07 0.943 %0207..90 8548543.8 .9.-014748904547488970...03990478033415488.0./03.92039 907. :.4:2-48.3..9..0398 3..9.72.908.-0.80901043147..703472.0 .479488 %$  7:. -4.947 $# 7.:/3-8548543.3/430..0-430708475943 9080.943$:22.340041!8.7090/974:90/30 ( ..9:70890390.92039  8548543.70:80/94/0.0594724/:..8.0.9007..90/0.5/ 0.90/8.70.50884:/-0...3.908 90800.0 0099-7.70.0  0/.-9410889.41030 ..70033 (  7949.81477050.9890841.0.00/900.92039   %0&$!$% 70.9203984148904547488  $00%70.3..-8548543..-8475942097  84:/-07050.-4.708475943 47.789..90. .903984.. 84:/-050714720/0.7835.9/0 .3/.039.1139147/74. 0307 7.7  8548543.07 89.7  397084759.3/5745480/ :/03081475.4:0841347.-4:94592.. 3907.390747853.908..:/0901443 %47..3.00897403 70./03.

 8548543.9203941 548920345.48904547488 4890454748832.3/970.03943.0/48904547488  '01:/7:31472.:8. .908.03/743.5574.08 .90814790570.2.9084/:2.70.3/89074/ 3/:.9084/:2 48.943 03/743.0/390&390/$9.

07  03/743..3/89074/ 3/:...08.23 03/743.808-4302307.808. ! 84:9439.3/343.94309 .0790-7.1074 48.. /4834.908.5574.3/743.0/147548920345.0/147970.0/48904547488  '01:/7:31472.5574.9908530-.07 98.3/905-    970/:..908..9084/:29.3/905-  9 70/:.0790-7.9084/:2 ..40.:8.3/905-  970/:.9:708- 4.943 #80/743.17.0394341548920345.0790-7.48904547488 2.:8.903.0300  '01:/7:31472..3/ 570.9084/:2 43.94341343.90 .9:708-4.0 48904547488 .9:708 -.08903.3/89074/ 3/:.89  .0/147970.-03.92039.70.347.0790-7./ #0.17.3/570...70..3/343.84.-09 47 &41 .70.943 -.908... 17.079.9430 780/743...0394341548920345.2../0389  .9:708-.9.08 ..8340110.92039.48904547488  '01:/7:31472.0/48904547488 9.17..903..!:8    03/743.0790-7.:2    #80/743.:2.7-43.0790-7...9908530- .3/743.9:708- 93907299039 343/.17..903.5574...3/743.    -.808.9843 70/:.9908530-   .041.943 40/743.-8.048904547488 .9:708-.:8.48904547488 2.17./03.

/8902489549039-8548543.9:708-4....70.9203941548920345.0/14790970.-0 93.7  !059/047243089.3/09..88$:22.3/343.9908530-    .89..5574.70/95.425.9048904./03.3/.48904547488  3/4.730.:8.924/:.0-4 970/:.08903..0418530 17.-4.808.  40/743.../8.0398 .3/905-   .17.. .0790-7.9:708- .90.9:708-  517.07 40/743...

9030-430-3.78530- .:8.08   //943.0-00384394-0 0110.-847594341.9:-:.3/..:2.80/ 970/:..7475443.0/8009.9.3090110...0412441907..07.7.39:2.9:70  %883..9:708-35.70...5574.. .3!%  .70.5 %075.:2.8/039.70.806:03.3/390893.425..7.-4.48904547488 70850..88.808-4307084759439.9..80/97.3!% %8.70.794892:.990:2-.9413./8 90-44.803/4034:8!% 9:870:.93.5844.-8475943 %075./3943.1907.7.039 ..3.808-4307024/039903090110.70/95.3/5485.90 .7-430.891:3.48904547488 47548920345..941 48904-.17.833:2-07. 3..9:70/:094572./:2.898 -430 14723..2.9.07043 41 .90398.7.4393:4:80548:7094!% .3/ /308 9478572.943 0.80/-4302.-4823-430.03 3907299039 !%3.941/0.0-4 03.9/0 47904    %  '01:/7:31472.:.234..0 ( '01:/7:31472.74.09490 90723.0/147203474203.7 70.:/070:.94383..3/905- ..70.9/03.943 %075.08907841853017.3.3/ 2574.9:708-.3/ 343853...943 .9/0870..4748904-.:2.98.808 .943..0390970.9...7.3/5485.4397./..9784117.-0.-482 703.234.90209.70.8994.4:20 !%57424908 30-4301472.9/08 .42-3.94341-430209.

.0394890454748835.89.08903.908.808.04117..78530-   970/:.3.3..94333.9:708  89:/08/484.....94338..90/ 93-9848904.    .9:708 94:347080./03.. /..5059/0472430:80/94970.7..041853017.3 479.08903.9433 .9:70-374:570.9433 .0.9.90398917.70.4397.08.990 :2-.9.70.3/0897403.84..3  &.0110.70.9835..943370/:..8:5547990/0./03.8..3/..88420.3/570.9.990:8041397.803990:8041..90/473499407..33.-430 708475943 9.90398342 -8548543.

9..39.03943.41030 .147282470 .943 #.5574.3/-099079407.9078147489045474884.:7.9.1907 24398990 5./ 98.8.9478 $#8 .410303.-034203 .9.0.9908530.    #.:80 0 491.-035.924/07.041853017.0110..703907.3..9.90/- 0897403-:9.0/14790570./. 48904547488 9824898:9.89..924/07.438947.03039..08903.3/970.0398 ..9203941548920345.0398 40.3/905 970/:.3/22:344.98420419070.9:708-  4.98410897403894:990..388902 0 0897403 9080.9.1472840.88$:22..0089740370.70.7  .0 31706:039./03..703907. 90574.3800.7  $00.808.3/4.88$:22.90/ 23:94341-030192.:8.90 94  78147-70.3.0897403#0.07 -0.05947 24/:.1472  $00...0594724/:..07  44.397084759.07800110.947 .4.3.842494782594284120345.4389 /0503/3439047..70.07 #..3/397.70.410308.059474/:.8.43.059478892:.8.07 90397.808 .:8041907800./090-0301.98  '01:/7:31472..

 39:73 0..:28:5502039.347/07943.:8.:2. .8-003574.3 .3.88$:22.05947.0/4907970.80-430/0389 '9.9570.70:80/943..90  ..9434148904.4148904.3/.4203948904547488.898 90.70...943 .90.97..70./8475749435:253-9478  8907.943 1:3.9.943 .908-09907.88 .:28:55020398.7  .803-4301472.908..:2$.087085438-0147-430708475943 983/. .:2.. /0..90   .-8475943 .947 .147.0-00384394-00110..9-3/8949070.90 0850./894..9..:2.9:708  '01:/7:31472.:2.43.97...903989.80-4302.94335..039901472.0..98 ..70.304784:-0574903088039.23.:20.39. .920394148904547488  '01:/7:31472.:2.7-43.- !74.9.0390 970.3/ 8:7.9..3/.08 ( ..    %8.2370509438 088039.-847-0/9..3/ # ..3/17.9:703548920345.2434.39-4/089.80.39-4/9.0394407903..7-43.3/3....238...943 0348:2.920398  '9.43..947413:..17.9:7078 0 894741 4890454749.90/14790570..0398.90398..71.898 ..     .9:70 1.23 97.041 17.97.147901472.434.03943 4117.70088039..943.4224314:3/43902..38202-7./03.3/.:2..97...:2.94:3.08.7-43.

039347/0.39:7370/:.88$:22.907.//943.9.8083908841 # .92039884:/-0.017423.0 .5.429..70.5.42548943412.804143..398 $:.0 41570.90897403 5740893907.70:80/943.03943  '01:/7:31472.3/ -09.90 .:8.7  %03.08 .0 /480.80807:2 08974030. 1742904203 80.:8.43974320345.907..514790570.0/ .30/0.709988:08   :950.5574.907 84:-008974038:1../4974538174259:9..0100/-.80907841-70.84:7.7/80.90/08974038708947008974030.943 43:.088..43.572. //7406:033  .5.84249478259428.:/3.94907 . //7406:033   43:.9745.:8.0894.73    %8.70..02039907.:773 .90/08974038 !702.43:.9.:80 ../.94330.7/4./14:3/943.90 9.89740307.79/80.3/2.83890.70.70..438/070/.784:/-0:80/ %070.0841.29:7041089740384-9.9   3905.94389.0/3430897403970..9908479089/:7.42203/89.884.5 3.89084/:28.8424947 8259428.43.9 43.438/070/178914748904547488570.0/14790570.809.939.8.039078 .93/:.70.4743. 0897.0397.9745 %0.0907841.0394341 548920345.439.439.. 8259428.08  70.425430398 84/:28:1.9041-430708475943  (%040890110..908  ../07.3.70:.89 0897403705.3.29:704184/:20897430 8:1.90/.80 48904-.984120345.3/70014120345.89.9841.:.9..039434148904547488.:.70.3/.3/2.7  897403/07.392.38 . 39:73 /0..4./90..039./49745.708 :730 98./4 .48904547488 897403.70..90.908-03/0/9470570803990.08-430708475943..3/.3/ 5708:259.:80708543/940897403705..80 40.850.08 .5574.5/408349 70/:.07 /..0/17425703.947.0.8470/:.39.38.808907.8.9.9:7.7907.3574903839.08.3/84/:206:38:1.

397084759.90/920345..9:907:8 ./4 897.3/.7-0/24701706:03914790570.0 '.943.89070.0/3.42039.9:708  '01:/7:31472.3. 70:.703.90 94 80..90/08974038.943 930897.    897.07 89740 .705708./.3/ 970..3/4./4 3.:80  '01:/7:31472.90/089740389457020345.//943 0.84249478259428 .94384:/-0:80/3548920345. 74:9305708.4..843-98 48904.:8.:94:8 70.0398.73 91706:0392439473  907. 897.3/94570.03943.943 43:.9.0894.3/.942 47548920345.0398    88:./49745.43:.00 2.0890700.804143.947..9.7-3.070.0100/-.93/:..42203/.89..08:0898.3/347093/7430 0279    930897.3574903839.70/:...:8.94389.0./03..0 .041 17./03..3//0.7 897.709988:089.8479 9072 4/48041!702.:8.0..42203/0/ %820/.0.924/07.42034.9203941489045474883548920345.4393039 ./497453817429059:9.03948904547488./47089470808974030.884...70.:8./49347093/74308:80/94970.034:89742-402-4./072 47.4203  '01:/7:31472.7.943 897..3/2.0397.03907898 39:73 70/:.43.8-430488 3.8089083908841 # .339./4.703490/7:841.030.42038349 70.9.

:8.43:.42-3.3/20/745740890743070/:.08-430708475943.-430488  .98548920345.09.94341.7/847.90/08974038.80    %0.20/7457408907430.3/ 709..90 !702574 !7025.